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ABSTRACT
A SIGNATURE ENRICHMENT DESIGN WITH BAYESIAN ADAPTIVE
RANDOMIZATION FOR CANCER CLINICAL TRIALS
Fang Xia, M.S.
Advisory Professor: Xuelin Huang, Ph.D.
Clinical trials in the era of precision medicine demand more flexible and efficient
trial designs. Adaptive clinical trial designs allow pre-specified modifications of an
on-going clinical trial and could shorten the trial duration. We reviewed five common
types of adaptive clinical trials based on adaptation methods. In particular, outcome-
randomization becomes more popular as it can assign more patients to the promising
treatments based on the accumulated trial data. This data-driven allocation allows
more patients to benefit from the trial, which is especially important for cancer
patients. We compared different Bayesian outcome-adaptive randomization methods
and discussed them from both methodological and ethical aspects.
When the group of patients who are likely to benefit from the test treatment is
known, the clinical trial should focus on that sensitive subpopulation. The use
of biomarkers in adaptive clinical trials can guide the assignment of individually
optimal treatments to patients. To address this objective, we proposed a cross-
validated signature enrichment design combined with Bayesian response-adaptive
randomization. We evaluated the performance of this design using four criteria
based on the benefits and losses for individuals inside and outside of the clinical
trial. The proposed design allows more patients to receive optimal personalized
v
treatments, thus yielding a higher response rate. This design can identify therapies
that are globally beneficial as well as treatments that are effective only in a sensitive
subset. Simulation studies demonstrate the advantages of the proposed design over
alternative designs. The approach is also illustrated by an example based on an
actual clinical trial in non-small-cell lung cancer.
In contrast to the traditional two-arm trial, an umbrella trial is a master protocol that
studies multiple drugs within a single indication, which can result in more accurate
and efficient drug development. Based on SEDAR, we proposed a SEDAR-U design
that is suitable for umbrella trials. We extended SEDAR to allow multiple arms and
incorporate an early termination rule. Simulation studies showed that the SEDAR-U
design can allow more enrolled patients to benefit from the promising treatment and
achieve favorable operating characteristics.
vi
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As the understanding of molecular, genomic, and phenotypic properties of
cancer emerge, novel clinical trial designs are pressingly needed to improve the effi-
ciency of drug development. Adaptive clinical trials allow pre-specified modification
to the trial as it proceeds, which may shorten the trial duration and require fewer
patients [4, 5]. Some common adaptation features in oncology trials include sample
size re-estimation, adaptive randomization, and interim monitoring. Adaptive de-
sign can be used in all phases of clinical development. Phase I clinical trials aim to
estimate the maximum tolerable dose (MTD) for the new drug, which is the highest
dose with acceptable side effects. The continual reassessment method (CRM) [6, 7, 8]
is an adaptive phase I trial that estimates the MTD based on a model instead of the
traditionally rule-based designs [9, 10].
Phase II clinical trials aim to identify the efficient new treatment that can
then be tested further in a phase III trial. The primary endpoint for a phase II trial
is usually tumor response (response/no response). Phase II oncology trials are often
single-arm, but may also be randomized [11, 12, 13]. Most adaptations have been
applied to phase II trials. Some common adaptations include adaptive randomiza-
tion, biomarker adaptive, sample size re-estimation, et al. Other than the frequentist
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framework designs [14, 15, 16, 17], Bayesian approaches permit modifications based
on accumulating data [18, 19].
Phase III clinical trials aim to evaluate the efficacy of the experimental treat-
ments compared with the existing therapies or standard of care. They are large-scale
randomized trials, typically consist of two or more treatment arms with hundreds
to thousands of patients. The primary endpoints for phase III oncology trials usu-
ally are the time-to-event outcome (progression-free survival, overall survival, and
disease-free survival) or binary outcome (response/no response). Phase III trials of-
ten include an interim analysis that allows early termination due to futility [5] and
follows intention-to-treat principle [20]. At the end of a positive phase III trial, the
experimental treatments will be submitted to the FDA for approval. The seamless
phase II/III trial is an adaptive design that promotes a more rapid transition be-
tween phases II and III by combining effectiveness assessment and confirmatory into
one trial [21, 22].
The rapid advancement of cancer biomarker development allows a better fit
between patients and treatment options [23, 24, 25]. There are two types of biomark-
ers based on usage: prognostic and predictive biomarkers. Prognostic biomarkers
provide clinical outcome information independent of treatments, while predictive
biomarkers directly link the clinical outcome information to a specific treatment.
If a treatment that targets a particular biomarker, such information can be used to
categorize patients into either “sensitive” or “non-sensitive” patient subgroups to fur-
ther assess the patients’ responses. When the group of “sensitive” patients who are
likely to benefit from the experimental treatment is known, the clinical trial should
focus on that sensitive subpopulation. Some predictive cancer biomarkers that have
been used to guide patient screening include human epidermal growth factor receptor
2
2 (HER2) for breast cancer [26, 27], BRAF for colorectal cancer and melanoma [28],
estimated glomerular filtration rate (EGFR) for non-small-cell lung cancer and col-
orectal cancer [29, 23]. Furthermore, in 2017, the FDA approves Pembrolizumab for
any solid tumor with the microsatellite instability-high (MSI-H) or mismatch repair
deficient (dMMR) biomarker marked the agency’s first approval based on biomarkers
rather than tumor location [30].
The emergence of translating biomarker information into clinical use calls for
more efficient and accelerated drug development. Master protocols is an overarching
protocol which concurrently operates multiple substudies to simultaneously evaluate
one or more interventions in one or more disease types, where each substudy may
be conducted based on tumor type or biomarker [31, 32, 33, 25]. Based on the
characteristics of the study, a master protocol is classified into basket, umbrella, and
platform trials. The basket trial evaluates one treatment for multiple diseases with
a common biomarker; the umbrella trial evaluates multiple treatments with each
sub-study targeting one biomarker for one disease type. The platform trials assess
perpetually several treatments for one disease and permit flexible addition and/or
exclusion of new treatments during the trial. If basket and umbrella trials allow the
addition of new therapies and exclusion of inferior treatments during the trial, they
can also be considered as platform trials [33].
This dissertation is organized as follows. In chapter 2, we provide an overview
of adaptive clinical trial designs. In chapter 3, we compare different Bayesian response-
adaptive randomization methods and discuss their application from methodological
and ethical considerations. In chapter 4, we propose a signature enrichment design
with Bayesian adaptive randomization (SEDAR) for cancer clinical trials. In chapter
5, we propose an extension to the SEDAR that incorporates an early termination
3
rule and allows multiple treatments for umbrella trials. In chapter 6, we conclude
with a brief discussion and future work.
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CHAPTER 2
Review of Adaptive Clinical Trial Designs
Traditional randomized clinical trial uses a fixed ratio to assign patients to
each treatment arm and analyze the treatment effect at the end of the study. In
recent years, adaptive designs have become increasingly popular because of its flex-
ibility as an alternative to traditional randomized clinical trials. Adaptive designs
allow modification of the on-going clinical trials according to the information col-
lected during the trial without undermining its integrity and validity. The use of
adaptive design is attractive to investigators, sponsors, and even patients because
it may reduce the trial duration, limit the number of patients exposing to the in-
effective/inferior treatments and increase the probability of success in later phase
drug development. Due to the modifications applied, some common types of adap-
tive designs include a) adaptive dose-finding, b) response-adaptive randomization, c)
adaptive group sequential, d) biomarker adaptive, e) seamless phase II/III. Details
of each design are described below.
2.1 Adaptive Dose-finding Design
The main objective of phase I clinical trials is to establish the maximum
tolerated dose (MTD) for phase II trials. One fundamental assumption is that the
efficacy of the drug monotonically increases with dose levels. However, as the doseage
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gets higher, the toxicity increases at the same time. If the dose level is too low, the
drug may not be efficient; if its too high, the drug may be too toxic. The MTD is
considered the optimal dose level. A well-designed dose-finding should achieve a high
probability of finding the MTD while limiting the number of patients being exposed
to the dose-limiting toxicity (DLT).
Dose-finding designs can be classified as rule-based design or model-based
design. The most widely used rule-based design is called “3+3” dose-escalation
design [9, 10]. Below is a simple example of the “3+3” design:
Suppose three patients enter the trial at the initial dose level M. If no patient
experience the DLT, then escalate to the next dose. If more than two patients
experience the DLT, then stop the trial and claim dose M is the MTD. If only one
patient has the DLT, then enter an additional three patients at the same dose level
M. If one out of the six patients has a toxic response, then escalate to the next dose
level M+1 ; Otherwise, stop the trial and claim dose M is the MTD. In summary,
the estimated MTD is the highest dose level with observed DLT less than 0.33.
Some alternative rule-based designs to the traditional “3+3” design include
the “2+4”, “3+1+1” and “3+3+3” designs [10].The main advantage of the rule-based
designs is easy implementation. However, it only utilizes the data at the current dose
to make the decision and may enroll many patients to the ineffective low dose levels
and expose some patients to the unsafe toxic dose levels [34, 35]. Some published
performance of the “3+3” design also shows that it has a low probability of selecting
the true MTD [36] and is highly variable in estimating MTD [35].
An adaptive dose-finding design based on a statistical model that proposed
by O’Quigley et al. [6, 7], the continual reassessment method (CRM), is a common
alternative to the “3+3” design. It uses a statistical model to estimate the relation-
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ship between the dose and the risk of experiencing a DLT. It is a Bayesian procedure
based on a one-parameter model. The CRM starts with a predefined set of dosages
and the target DLT that defines the MTD, and then uses Bayes theorem to update
the distribution of MTD continuously. After observing each patient’s response, the
posterior distribution of model parameters and predicted probabilities of a toxic re-
action at each dose level are updated. The dose level for the next patient is chosen as
the one with the predicted toxicity response probability closest to the target level of
response. This procedure is repeated until the requisite N patients are enrolled. The
final estimate of the MTD is the dose with the closest posterior probability to the
target DLT. Additional model-based designs based on CRM includes dose escalation
with overdose control EWOC [37], Bayesian model averaging CRM [38], time-to-
event CRM [39] and Bayesian logistic regression model (BLRM) [40] etc. Although
CRM has shown more desirable operating characteristics than the rule-based designs
including a higher probability of determining the true MTD, its application is still
limited due to conceptual and operational complexities [41].
Recently, another type of adaptive dose-finding design that combines key el-
ements of the rule-based and model-based designs named model-assisted designs.
Similar to rule-based designs, their dose escalation/de-escalation rules can be deter-
mined before the start of the trial. It also borrows the strength from model-based
designs by using a statistical model to aid decision making. Some examples include
the modified toxicity probability interval (mTPI) design [42] and its variation mTPI-
2 [43] and the Bayesian optimal interval (BOIN) design [44].
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2.2 Response-adaptive Randomization Design
Traditional clinical trials use a fixed ratio to allocate patients among treat-
ment arms. Adaptive randomization allows modification of the allocation probabil-
ities based on accumulated patient responses (outcome). This adjustment enables
more patients to receive superior treatments at that moment, limits patients expos-
ing to the subtherapeutic therapies, and potentially results in more accurate and
faster drug development. Response-adaptive randomization may be conducted con-
tinuously throughout the trial, or as a one-time adaptation in the allocation ratio at
the time of an interim futility analysis. Response-adaptive randomization can also
be approached from the Frequentist and the Bayesian framework.
A Frequentist approach named doubly-adaptive biased coin design was first
proposed by Eisele and Woodroofea [45] and further modified by Hu and Zhang [46].
This design depends on the current proportion of patients from each treatment arm
and the current estimate of the desired allocation proportion. The advantages of this
design include flexibilities to target any given allocation and allowing multiple types
of responses while attaining the lower bound of variance.
Figure 2.1 presents a diagram of the doubly-adaptive biased coin design. In
general, it consists of three steps: first, assign a small proportion of patients using
equal randomization as a burn-in period; second, calculate the optimal allocation
probability based on current patient responses. third, apply the allocation function
to calculate the assignment probability for the next new patient, which targets the





Assign treatment & Collect response
Figure 2.1: Diagram of the Doubly-adaptive Biased Coin Design.
To calculate the optimal allocation probability, the Neyman allocation [47] is
a popular choice. For two treatment scenarios, one may also consider the RSIHR
proportion [48] to minimize the number of failures. Some discussion of generalizing
the RSIHR proportion for K treatments has been discussed in Tymofyeyev et al.
[49].
Let k denote the treatment arm index, k = C,E, nk denote the intermediate
sample size, n = 1, ..., N, and πk refers to the response probability for arm k. Suppose
the allocation probability after step 2 is ρk and the allocation function g(r, s) which
is defined on [0, 1]× [0, 1] is as follows [50, 46]:





, k = 1, · · · , K,
where γ ≥ 0 is a tuning parameter that controls the randomness.
Then the assignment probability of treatment k for the next incoming patient
is g(nk/N, ρ̂k), where nk/N is the current proportion of patients in arm k.
In contrast to the Frequentist approach, Bayesian response-adaptive random-
ization assumes the randomization probability rk,n is proportional to the posterior
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probability [51, 52, 18, 53]:
Pr(πk = max{π1, ..., πk}| datan), k = 1, ..., K,
When n is small, the posterior probabilities can be highly variable. To stabilize the
randomization probability, we add a tuning parameter c such that
rck,n =
(Pr(πk = max{π1, ..., πk}| datan))c∑K
j=1(Pr(πj = max{π1, ..., πj}| datan))c
.
The value of c should be between 0 and 1. When c is equal to 0, it gives equal
randomization. When c is equal to 1, the rck,n is the same as r̂k,n = P̂ r(πk =
max{π1, ..., πk}| datan). In practice, c is usually set at 1/2.
Another method to control the randomization magnitude is to let the posterior
probability be the randomization probability rk,n, and restrict it within a reasonable
range. More details of Bayesian response-adaptive randomization will be discussed
in chapter 2.
2.3 Adaptive Group Sequential Design
Classical group sequential designs repeatitively apply significance testing at
pre-specified stages based on accumulating data. At each stage, it offers a possibility
of stopping early without the need of setting a fixed number of sample size. At each
interim stage, a decision may be made to support or reject the null hypothesis based
on a stopping criterion. A classical group sequential design requires to pre-specify
the total number and the timeing of the analyses. The trial will be stopped until
the maximum information is obtained or when crossing a stopping boundary. Let δ
denote the treatment difference between experimental and control groups. Suppose a
total number of K analyses, k = 1, ..., K, are planned with a maximum trial duration
allowed T . Let tk be the time of the k
th analysis, where 0 < t1 < t2 < ... < tk = T .
10
Thus, there is k−1 interim analyses and one final analysis. Let τk denote the fraction









where Nmax is the maximum requisite sample size for the trial and Dmax is the
maximum number of events required for the trial. They are often referred to as the
maximum information.
Due to multiple testings in the group sequential design trial, Type I error rate
will be inflated. To preserve the Type I error rate at α, we need to determine the
stopping boundaries c1, c2, ..., ck such that the trial will be stopped under H0 at the
first τk when
|Z(τk)| ≥ ck.
That is, to select a ck such that P0(
⋂K
j=1 |Z(τk)| < ck) = 1 − α. Examples of the
stopping boundaries include the Pocock [54], the O’Brien & Fleming (OBF) [55],
the Wang & Tsiatis [56] and the Lan & DeMets [57]. The Pocock uses constant
boundaries [54], while the O’Brien & Fleming utilizes increasing boundaries [55].
The Wang & Tsiatis boundaries depend on a shape parameter and the pre-specified
information fraction [56]. The Lan & DeMets proposed a flexible boundary approach
called the α spending function without requiring a pre-specified number of interim
analyses and the timing of those stops [57].
The α spending function α∗(τ) is a monotone increasing function of τ which
defines how much α is spent at each τ [58]. For τ0, α
∗(0) = 0; for τK , α
∗(τK) = α.
The stopping boundaries ck is solved recursively from
P0(|Z(τ1)| ≥ c1) = α(τ1) for k = 1;
11
α(τk−1) + P0(|Z(τ1)| < c1, ..., |Z(τj−1)| < cj−1, |Z(τj)| ≥ cj) = α(τj) for k = 2, ..., K.
The α spending function can also approsimates the O’Brien & Fleming [55] and the
Pocock group sequential boundaries [54].
To determine the requisite sample size for a group sequential design, we first
need to specify α, the spacing, the number of analyses, desired power β and α∗(τ) to
compute the stopping boundaries. Then compute the required maximum information
Imax in order to reach the desired power based on the stopping boundaries. The final
step is to convert Imax into Nmax for quantitative endpoints or into Dmax for time-
to-event endpoints.
Adaptive group sequential design allows adaptations or modifications at in-
terim analyses [59]. Those adaptations may include but not limited to sample size
re-estimation, adding/dropping treatment arm, randomization scheme modification,
etc. Although the classical group sequential design is well understood and the Type
I error rates can be well controlled under spending functions, adding changes at in-
terim analysis may inflate Type I error rate. Statistical procedures are still needed
to control study-wise Type I error rate [60].
2.4 Biomarker Adaptive Design
A biomarker is a biological molecule that is objectively measured and eval-
uated as an indicator of normal biological, pathogenic processes, or pharmacologic
responses to a treatment[61]. The emergence of biomarker development can guide
treatment selection for patients according to their biological characteristics or ge-
nomic profiles. Based on the type of usage, biomarkers can be classified into prog-
nostic or predictive biomarkers. Prognostic biomarkers assess patient responses inde-
pendent of treatment, while predictive biomarkers provide information regarding the
12
most likely response to a given treatment. Prognostic biomarkers can separate po-
tential patients into good or poor prognosis at diagnosis, while predictive biomarkers
can separate patients into sensitive or non-sensitive for a given treatment [62]. Based
on the characteristic of predictive biomarkers, they can be used to guide treatment
selection to allow a better fit between patients and treatment options.
Many molecular cancer treatments only benefit a subset of patients. Biomarker
adaptive design identifies a subgroup of patients who are most likely to respond to
the test treatment based on their biomarker profiles. Biomarker adaptive design
can allow more patients to benefit from the trial compared to the traditional all-
comers design, which may increas the trial efficiency and limit non-sensitive patients
to experience the toxicity of the test treatment.
Xu et al. propose a subgroup-based adaptive (SUBA) design for multi-arm
biomarker trials [63]. The SUBA design simultaneously searches for prognostic sub-
groups using a random partition model and assigns patients to the best subgroup-
specific treatment based on posterior predictive probabilities.
If a biomarker is known at patient screening, this trial should only enroll
sensitive patients. If the biomarker information is unknown, the adaptive signature
design [1] may be used. The adaptive signature design tests the overall treatment
effect at a significance level of α1. If the overall treatment effect is statistically
significant, then conclude that the experimental treatment may benefit all treated
patients. Otherwise, test the treatment effect in a sensitive patient subset at a
significance level of α2. This controls the overall type I error rate at α with α =
α1 + α2.
Jiang et al. proposed a biomarker-adaptive threshold design procedure to
evaluate treatment with possible biomarker defined subset effect [64]. Their proce-
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dure combines both overall and subset tests by incorporating a correlation structure
of the two-stage test statistics. Their simulation and real trial data application show
that the biomarker-adaptive design substantially improves the efficacy compared with
the traditional design. Specifically, their design consists of two procedures: proce-
dure A which is similar to the adaptive signature design [1] and procedure B which
combines testing treatment effect for both overall and sensitive patients. Procedure
B incorporates a correlation structure of the two-stage test statistics from procedure
A. It only chooses the maximum statistic T from all the cut-off models, each corre-
sponding to a potential biomarker cut-ff value. To ensure the power is adequate when
the test treatment is indeed beneficial to all treated patients, a positive constant R
is added to the overall effect statistic S, whose value is calculated when cut-off value
= 0. Then the permutation distribution of the test statistic T is used to calculate
the P value.
Gu et al. proposed a Bayesian two-stage biomarker-based adaptive random-
ization design (BATTLE-2) [65]. This design has three main goals: 1) to test the
treatment effect 2) to identify prognostic and predictive biomarkers for targeted
agents 3) to provide better treatment for patients enrolled in the trial. Bayesian
adaptive randomization approach applies to both the biomarker development (stage
I) and validation stages (stage II). In stage I, adaptive randomization is applied based
on a known biomarker. At the end of the first stage, a Go or No-Go decision is made
from testing the overall treatment effect. If a Go decision is made at the end of stage
I, a two-step Bayesian Lasso strategy will be used to select additional prognostic or
predictive biomarkers based on the accumulated data: group lasso will be used to
select important biomarkers, and adaptive lasso will be used to refine the selection
and estimation. Patients enrolled in the second stage will receive treatment based
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on the refined adaptive randomization scheme.
2.5 Seamless Phase II/III Design
During traditional drug development, phase II trials select the best treat-
ment/dose, and phase III trials further confirm the treatment efficacy. The seamless
phase II/III design (also called pick-a-winner design, drop-the-loser design, adaptive
seamless design) is a multi-stage design that combines phases II and III into a single
trial. It consists of two stages: a selection stage (phase IIb) and a confirmation
stage (phase III) [66]. For the selection stage, the objective is to select the best
dose/treatment by employing a parallel design with multiple treatment arms and a
control arm. The inclusion of a control arm at the selection stage allows the data
to be easily combined with that from the confirmation stage for final analysis. The
confirmation stage evaluates the efficacy of the selected treatments versus the control
treatment.
The general framework for a seamless phase II/III design is as follows: patients
entering the trial are randomized between the experimental arms and the control
arm. At the end of the first stage, the selected dose/treatment will move to the
confirmation stage. Newly enrolled patients will be randomized to receive the selected
dose/treatment or the control treatment. If multiple arms are selected at the end of
the first stage, or only the inferior treatments are dropped, each selected arm will be
compared with the control arm at the confirmation stage.
Thall, Simon, and Ellenberg proposed a two-stage design with binary end-
points to avoid continuous monitoring [67]. Schaid, Wieand, and Therneau extended
their design to the time-to-event endpoint and allowed early stopping for efficacy af-
ter the selection stage [68]. Stallard and Todd generalized their designs to allow more
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than two stages using error spending function and suitable for all types of endpoints
by using an efficient score for test statistics [69]. Huang, Liu, and Hsiao presented
a seamless design that allows pre-specifying the probabilities of rejecting an arm at
each stage [70]. Bischoff and Miller proposed a two-stage adaptive design based on
the means of the normal distribution for treatment selection [71]. Their design re-
quires a minimal number of patients to reach the desired power while controlling the
type I error rate and limiting the probability of selecting an inferior treatment after
the first stage. Todd and Stallard presented a group sequential design that allows a
change of endpoint for the confirmation stage [72]. Chow and Tu derived formulas
for sample size calculation, assuming the same study objectives at different stages
[73]. Posch, Maurer, and Bretz presented two methods to control the type I error
rate when applying sample size reassessment and/or treatment selection: one uses
simulation to adjust the critical value, and the other uses an adaptive Bonferroni-
Holm procedure [74]. Stallard described a method to control the type I error rate
by adjusting the usual group sequential boundaries when using short-term endpoint
for the treatment selection at the first interim analysis for a confirmatory seamless
phase II/III trial[75].
Instead of running multiple experimental arms vs. control arm phase II and
III designs, the seamless phase II/III design requires a smaller sample size by utilizing
data from both stages and can expedite the drug development process [76, 66]. Since
the results of a seamless II/III trial is sensitive to the timing of the analysis for the




Comparison of Bayesian Response-adaptive Randomization
Methods
When designing a clinical trial, equal randomization is commonly used. How-
ever, many argue that it is not ethical to assign the same number of patients to poor
treatment and to more efficacious treatment. Response/Outcome-adaptive random-
ization aims to assign more patients to the superior arm based on the information
of current patients’ performance accumulated as the trial moves along. Although
response-adaptive randomization offer many advantages, it has raised some concerns
over its complexity in design and coordination, and the difficulty in informing pa-
tients and its validity. In this chapter, we compare two Bayesian response-adaptive
randomization approaches and discuss them from the methodological and ethical
considerations.
3.1 Comparison of Different Bayesian Response-adaptive Randomiza-
tion Methods with Fixed Randomization
When designing a clinical trial for comparing two or more treatments, equal
randomization is commonly used. However, in many cancer clinical trials, patients
need to enroll in trials to receive the most advanced therapies. Therefore, it is essen-
tial for the trial to offer maximum treatment benefits to the participants. In early
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oncology, we may find response-adaptive randomization [77, 78, 50, 79] attractive
as it assigns more patients to receive the superior treatment based on current data
evidence, which offers patients a higher chance to benefit from enrolling in the trial.
Figure 3.1 presents the diagram of a general Bayesian response-adaptive ran-
domization procedure. A key feature of Bayesian response-adaptive randomization is
that it repetitively updates the assignment probability based on accumulated data.
Burn-in
Compute posterior probability 
Update randomization probability
Assign treatment & Collect response
Figure 3.1: Diagram of the Bayesian adaptive randomization.
Consider the design of a two-arm clinical trial to compare treatment A to
treatment B to study the efficacy. AssumingXi is the operating characteristics/biomarkers
for patient i. For the Adaptive Randomization Using Response Rate approach
(ARRR), the probability of assigning patient i to each treatment arm is computed
using the estimated response rates if he/she were received treatment A or B.
Let r(A,Xi) and r(B,Xi) denote the response rate which if patient i receive







where w is a tuning parameter that controls the magnitude of the randomizaion.
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Another method called Adaptive Randomization Using Superiority Confi-
dence (ARSC) uses the posterior probability P (r(A,Xi) > r(B,Xi)|data) to cal-
culate the probability of treatment assignment. ARSC assumes the allocation prob-
ability for treatment A is proportional to the posterior probability P (r(A,Xi) >
r(B,Xi)|data). The probability of receiving treatment A when using AR-SC, Pi,A,AR−SC ,
is defined as
(3.1) Pi,A,AR−SC =
P̂ (r(A,Xi) > r(B,Xi)|data)
w
P̂ (r(A,Xi) > r(B,Xi)|data)
w
+ P̂ (r(A,Xi) ≤ r(B,Xi)|data)
w .
Here we use a simple example to illustrate the main difference between ARRR and
ARSC (Table 3.1). At the beginning of the trial, suppose each arm currently has 10
patients and the response rate is 0.6 for arm A and 0.3 for arm B. The probability
of being assigned to arm A when using ARRR is 0.67 and when using ARSC is
approximately 0.52. Later, suppose each arm reaches 100 patients and the response
rate for each arm remains the same. The probability for ARRR still stays at 0.67,
while that for ARSC increases to 0.70.
Table 3.1: A simple example: ARRR vs. ARSC
nA = nB = 10 rA = 0.6 rB = 0.3 PA,ARRR = 0.67
PA,ARSC ≈ 0.52
nA = nB = 100 rA = 0.6 rB = 0.3 PA,ARRR = 0.67
PA,ARSC ≈ 0.70
According to this example, with only 10 patients, the superiority of treatment
A is unclear. Aggressive patient allocation to treatment A is not appropriate. How-
ever, with 100 patients, the superiority of treatment A is clear. Aggressive patient
allocation to treatment A is desired. This simple example shows that PA,ARRR re-
mains the same regardless of sample size; PA,ARSC increases as the sample size gets
larger.
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We further compare the performance of ARRR and ARSC in a clinical trial
setting through simulation. We use the following logistic regression model for patient
responses:
logit(ri) = β0 + β1Ti + β2Xi + β3TiXi
k = A,B; i = 1, ·, N.
where Xi is the patient biomarkers. We write X ∼ Normal(µ, σ2) to indicate that
the random variable X has an normal distribution with mean µ and variance σ2. Let
Ti denote the treatment indicator which
Ti =

0.5 Treatment = A
−0.5 Treatment = B
, i = 1, ..., N.




, i = 1, ..., N,
where each patient’s response follows a Bernoulli distribution with probability ri.
The required design parameters and the simulation settings are presented in
Table 3.2: the sample size N ; the type I error rate α; the initial number of equally
randomly assignment patients neq; the adaptive randomization block size bl; the
tuning parameter w and patient biomarker X. The simulation scenarios are listed
in Table 3.3. For this simulation study, we focus on the overall response rates and
power. The results are presented in Table 3.4.






Xi i.i.d. N(0, 1)
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Table 3.3: Simulation scenarios
β0 β1 β2 β3
NULL -0.20 0.00 0.00 0.00
Scenario 1 -0.20 1.20 0.15 1.60
Scenario 2 -0.20 1.20 0.15 0.50
Scenario 3 -0.20 0.90 0.15 1.60
Scenario 4 -0.20 0.90 0.15 0.50
Table 3.4: Simulation results
Randomization Power ORR
NULL ER 0.036 0.450
ARRR 0.038 0.449
ARSC 0.033 0.450
Scenario 1 ER 0.953 0.458
ARRR 0.944 0.492
ARSC 0.920 0.519
Scenario 2 ER 0.982 0.457
ARRR 0.980 0.472
ARSC 0.980 0.490
Scenario 3 ER 0.767 0.458
ARRR 0.755 0.485
ARSC 0.707 0.510
Scenario 4 ER 0.856 0.453
ARRR 0.840 0.463
ARSC 0.831 0.475
For the given values of the design parameters, ARSC clearly shows advantages
from the increased response rates compared to ER and ARRR. The power, however,
is the highest with the trial using ER. This results agrees with the finding from
Lee, Chen and Yin [81]: using response-adaptive randomization may often result in
some power loss. However, an example in status epilepticus has shown that applying




Yin, Chen and Lee [81] proposed a phase II trial design: Bayesian adaptive
randomization and predictive probability (BARPP) which implements response/outcome-
adaptive randomization. This design is motivated by a neoadjuvant lung cancer trial
at the University of Texas M.D. Anderson Cancer Center. Since the sample size of
each arm is unknown due to the response-adaptive randomization mechanism, but
such information is required to compute the predictive probability, they proposed
two methods to approximate the predictive probability. In general, the predictive
probability is defined as:






P (Y1 = y1|X1 = x1)P (Y2 = y2|X2 = x2)
× I{P (|p2 − p1| > δ|X1 = x1, X2 = x2, Y1 = y1, Y2 = y2) ≥ θT},
(3.2)
where Yk is the number of future responses in arm k, pk is the corresponding response
rate, the number of response observed Xk, the maximum number of patients Nk, and
the number of patients currently in arm k, nk, k = 1, 2. δ is the clinically meaningful
treatment difference and θT is a threshold probability.
The decision rule based on PP is defined as[83]:
• Equivalence stopping: Stop the trial and claim the two arms are equivalent if
PP < θL;
• Superiority stopping: Stop the trial and claim a superior arm if PP > θU .
Type I error rate and statistical power are maintained by calibrating (N, δ, θT , θL, θU).
In outcome-adaptive randomization clinical trials, N1 and N2 are not fixed. The au-
thors proposed two methods to compute the PP .
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Recall that outcome-adaptive randomization assigns each newly enrolled pa-
tient to a treatment group based on his/her randomization probability. Randomiza-
tion probability is calculated based on cumulative information from currently enrolled
patients in both arms. It can be denoted following the work of Thall and Wathen
[80] as:
(3.3) π =
P (p2 > p1|X1 = x1, X2 = x2)τ
P (p2 > p1|X1 = x1, X2 = x2)τ + {1− P (p2 > p1|X1 = x1, X2 = x2)}τ
,
where π is the probability of assigning to arm 2 and τ is the turning parameter which
controls the rate of adaptive randomization. τ is recommended to take value between
0 and 1. When τ = 0, it is equivalent to equal randomization and when τ = 1, it is
equivalent to “play the winner” [84]. The results can be generalized to multiple arms
setting with one standard treatment arm and k-1 experimental treatment arms.
Method 1 calculates PP through averaging Y1 and Y2 conditional on the num-
ber of patients who would be assigned to arm 2. Let m denote the fixed number of
remaining patients in the trial and Z denote the number of patients who would be








PZ(z|X1 = x1, X2 = x2)× P (Y1 = y1|X1 = x1)P (Y2 = y2|X2 = x2)
× I{P (|p2 − p1| > δ|X1 = x1, X2 = x2, Y1 = y1, Y2 = y2) ≥ θT}.
(3.4)
Method 2 directly approximates Nk−nk based on observed data. For example,
N1 − n1 = m(1− π) for arm 1 and N2 − n2 = mπ for arm 2.
The authors perform simulations to further investigate the performance of
Bayesian adaptive randomization and predictive probability under various p1 and p2
combinations while fixing N, δ, θT and θU . Since no information is available at the
beginning of the trial, equal randomization is applied. As the trial proceeds, more
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patients are assigned to the better performing arm and lead to higher randomization
probabilities.
For the given values of the design parameters, the Bayesian adaptive random-
ization trial and predictive probability design and group sequential design produce
almost identical power curves. Under a certain scenario, the power when using
Bayesian adaptive randomization and predictive probability design is lower than
using group sequential design. The authors explain that this is due to the conserva-
tive approach group sequential taken to control type I error. The simulations also
show that when the difference between the two response rates is substantially large,
the response percentage in the superior arm when using outcome adaptive design is
higher since more patients are assigned to that arm compared to fixed randomiza-
tion. However, the required sample size for a response-adaptive randomization trial
is also larger than the trial using fixed randomization given the same type I error
rate and the statistical power.
When early termination is allowed, trials using outcome-adaptive random-
ization does not necessarily result in a larger sample size than the ones using fixed
randomization. If the treatment difference is large, early termination rule kicks in and
terminates the trial early. Thus, the sample size during the adaptive randomization
stage may be small, which may lead to a smaller total sample size.
The authors also note that since Bayesian adaptive randomization and pre-
dictive probability design assign more patients to the superior arm, the imbalance
between two arms increases accordingly. Thus, more patients are needed to make up
for the loss of statistical power, leading to a larger sample size needed for Bayesian
adaptive randomization and predictive probability design compared to fixed random-
ization.
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Lee, Chen, and Yin [81] also exam the operating characteristics of outcome-
adaptive randomization and compare it with fixed randomization for binary outcome
through simulations. For binary outcomes, patients either respond to the treatment
or not. In the content of a two-arm trial, let p1 denote the response rate of the control
arm and p2 denote the response rate of the experimental arm. The experimental
arm is declared as superior to the control arm if Pr(p2 > p1|D) > θT conditional on
observed data D and pre-specified cut-off value θT . The randomization probability
of assigning a patient to arm 2 is
(3.5)
Pr(p2 > p1|D)c
Pr(p2 > p1|D)c + Pr(p1 > p2|D)c
,
where c is the turning parameter.
For their simulation studies, the authors aim to control 10% type I error rate
and to reach 90% statistical power. They consider two turning parameter c values:
c = n/(2N) and c = (n/N)0.1, n is the current patients in the trial and N is the
total sample size. When c = n/2N , at the beginning of the trial c = 0 and at the
end of the trial c = 0.5. When c = (n/N)0.1, this reflects a larger contrast: c = 0 at
the beginning of the trial, c = 0.87 when 25% of patients in the trial, c = 0.93 when
50% of patients in the trial and c = 0.97 when 75% of patients in the trial. p1 is
fixed at 0.2 and p2 ranges from 0.05 to 0.95. Beta(1, 1) is the prior distribution. The
null hypothesis is defined as p1 = p2 = 0.2. The alternative hypothesis is defined as
p1 = 0.2, p2 = 0.4. The randomization probability is restricted between 0.1 and 0.9
to avoid extreme patient allocation.
The simulation results show that the number of the sample size required to
achieve the requisite power is the smallest for equal randomization and the largest
for outcome adaptive randomization with c = (n/N)0.1. Outcome adaptive random-
ization with c = (n/N)0.1 yields the highest overall response rate for all p2 value,
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especially when the difference between the two response rates is large. The number of
nonresponders is the lowest for equal randomization when p2 < 0.6, but for outcome
adaptive randomization with c = (n/N)0.1 when p2 ≥ 0.6.
When early termination rule is incorporated, the early efficacy and futility
stopping rates are similar between outcome adaptive randomization and equal ran-
domization. On average, the sample size for outcome adaptive randomization with
c = (n/N)0.1 is larger than those of equal randomization, but those of outcome
adaptive randomization with c = n/2N is similar to equal randomization.
Their simulations show that the trial using equal randomization requires a
smaller sample size and produces smaller non-responders while controlling type I
error rate and maintaining the desired statistical power than that using outcome-
adaptive randomization. While outcome-adaptive randomization often requires a
larger sample size, it allocates more patients to the superior treatment arm. Given
the same total sample size, outcome-adaptive randomization tends to yield a higher
number of responders than equal randomization. When the response difference is
substantially large, outcome-adaptive randomization may require a smaller sample
size and yield a higher response rate than equal randomization when early termina-
tion rule applies.
3.3 Ethical Considerations
Randomized clinical trials have always been treated as the golden standard
of conducting clinical trials. Thus, it is natural to compare outcome-adaptive clin-
ical trials with fixed randomized clinical trials. Many literature has discussed the
advantages and disadvantages of outcome-adaptive clinical trials and fixed random-
ized clinical trials from theoretical and methodological considerations, but it is also
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important to consider from the ethical perspective.
Hey and Kimmelman stimulates a discussion between outcome-adaptive allo-
cation trials and fixed randomized clinical trials in ethical considerations [85]. The
authors argue that outcome-allocation adaptive trials are no better than fixed ran-
domized clinical trials regarding mainly minimizing patient burden, informed con-
sent, and validity in the setting of two-arm trials, but may be more appropriate
in the multi-arm context. The authors claim that outcome-adaptive randomization
fails to minimize patients’ burden since only 50% success rate of achieving regula-
tory license after reaching phase III which implies that patients in outcome-adaptive
randomization trials still only have a 50% probability of receiving the superior treat-
ment in best case scenario. They also point out that most new treatments only
deliver minimal improvement over standard treatments, therefore one must justify
the disadvantage of the need for a larger sample size. The authors continue their ob-
jection that since outcome-adaptive randomization is complicated in nature, which
increases patients’ burden in understanding the informed consent. For validity, the
authors highlight that the dynamic trial environment and treatment may also induce
bias. They also point out since treatment allocation is based on currently enrolled
patients, the latter enrolled patients will have more advantage of being assigned to
a better performance arm than earlier enrolled patients. This may introduce bias
too. However, the authors believe outcome-adaptive randomization provides more
benefits than a fixed randomized clinical trial in the context of multi-arm trials since
it can evaluate many different hypotheses at once. In summary, Hey and Kimmel-
man found that outcome-adaptive randomization shows no advantage than a fixed
randomized clinical trial regarding patients’ burden, informed consent, and validity,
but maybe more appropriate in the multi-arm trial setting.
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The article by Hey and Kimmelman stimulates discussions over the ethical
consideration of outcome-adaptive randomization clinical trials. Many statisticians
have expressed their opinions corresponding to the arguments that Hey and Kim-
melman brought up to.
Joffe and Ellenberg express their opinions on outcome-adaptive randomiza-
tion from three ethical research criteria: scientific validity, favorable benefit/risk
ratio, and informed consent, with a focus on the data monitoring perspective [86].
They note that researches need to justify participants’ risk in producing generaliz-
able knowledge. In outcome-adaptive randomization trials, latter enrolled patients
may differ from earlier enrolled patients systematically. This results in imbalanced
allocation, and therefore introduces bias. They mention that outcome-adaptive ran-
domization improves benefit/risk balance for enrolled patients, particularly if the
superior treatment effect can be observed in a short amount of time. The authors
highlight that fixed randomization with sequential design may be the optimal ap-
proach when the goal of the trial is to minimize the number of patients enrolled in the
poor performance arm, especially with large difference outcomes. The authors par-
ticularly provide three plausible disclosure approaches in open-label adaptive trials:
first, investigators only reveal randomization without emerging data plan; Second,
investigators may disclose the dynamic treatment allocation probabilities based on
interim data, but withhold the prospective randomization probabilities for newly en-
rolled patients; lastly, investigators may inform patients both the adaptive random-
ization design and the actual randomization probabilities, which presents a difficult
communication challenge. In all scenarios, investigators need to address the fact to
patients that it is still possible that they will be randomized to receive the worse
performing arm.
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Korn and Freidlin [87] see no evidence that outcome-adaptive randomization is
useful, especially compared to equal randomization with interim monitoring. Interim
monitoring shares the same goal as outcome-adaptive randomization: to minimize
patients being assigned to the inferior arm. They mainly consider the operating
characteristics of trial designs with interim monitoring. They point out that although
outcome-adaptive randomization may provide a slightly larger proportion of positive
responders than fixed randomization design, outcome-adaptive randomization tends
to results in a larger proportion of non-responders due to the larger sample size
required. If the null hypothesis is true, outcome-adaptive randomization trial shows
no benefit since it requires a larger sample size, which will expose more patients to
the inferior treatment and result in a longer trial.
Although many statisticians question the use of outcome-adaptive random-
ization, Berry [88] strongly disagrees with Hey and Kimmelman’s opinions about
the unethical news of outcome-adaptive randomization. Berry argues that the au-
thors failed to understand the fundamental goal of clinical trials. The major goal
of conducting clinical trials is for scientific efficiency, not for better treatment for
participants. Since the conflict between clinical practice and science is inevitable,
the Belmont Report provides a guideline on how to deal with this situation. Adap-
tive clinical trials provide a better option than fixed randomization especially for
rare diseases, and they can also make an adjustment to multiple objectives under a
two-arm trial setting in a more efficient and timely manner. Berry also points out
that fixed randomization will be outdated with rapid advancement in oncology and
being adaptive can treat participants more efficiently.
Lee comments on the ethical issues from three categories: statistical proper-
ties, practical considerations, and real-life performance [89]. Lee states that equal
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randomization is in collective ethics, adaptive randomization is in individual ethics.
While keeping the desired statistical power, equal randomization is designed to have
the smallest trial to test treatment differences, but adaptive randomization focuses
more on providing the best treatment to enrolled patients. Lee argues that short term
efficacy often fails to translate to long term efficacy which may be due to poor choice
of surrogate endpoint regardless of randomization methods used. The low success
rate of phase III trials is mainly because of the inefficiency of the drug development
process. Lee also points out that adaptive randomization may utilize more resources
than equal randomization, but it takes patient benefit into account. Regarding the
informed consent concern raised by Hey and Kimmelman, Lee believes this is rather
a communication challenge instead of a randomization issue. Lee agrees that popula-
tion and treatment changes during the trial may induce bias, solutions such as block
randomization may be applied. Additionally, Lee encourages putting more effort in
educating adaptive randomization and in utilizing adaptive randomization.
Saxman shares some opinions with Lee that there is no sufficient evidence to
support Hey and Kimmelman’s argument that outcome-adaptive randomization has
no advantage over fixed randomization due to the low success rate of phase III clinical
trials [90]. Saxman objects Hey and Kimmelman’s argument that the complicated
to plan and coordinate the nature of outcome-adaptive randomization is an ethical
predicament for outcome adaptive randomization. On the patient autonomy issue,
particularly informed consent, Saxman agrees with Hey and Kimmelman that it is
difficult for patients to comprehend outcome-adaptive randomization due to its com-
plexity and the outcome-adaptive randomization supporters need to propose a more
effective solution to this problem. In continue with Hey and Kimmelman’s argument
on informed consent, Saxman also supports that outcome-adaptive randomization
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may have an increasing bias due to the dynamic entities.
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CHAPTER 4
A Signature Enrichment Design with Bayesian Adaptive
Randomization
4.1 Introduction
Most human cancers are heterogeneous with respect to their molecular, ge-
nomic and phenotypic properties and treatments that target specific molecules may
only benefit a subset of patients [91, 92, 93, 94, 95, 96, 97]. Thus, it is important to
design efficient trials that offer optimal treatments for as many patients as possible
based on their biomarker profiles.
In contrast to traditional non-adaptive design methods, adaptive designs have
recently gained popularity due to their flexibility and efficiency. In 2006, the Pharma-
ceutical Research and Manufactures of America (PhRMA) Working Group defined
an adaptive design as a design that allows modification of the on-going study based
on accumulating data, without undermining the validity and integrity of the trial
[98]. Examples of adaptive designs include those that use adaptive randomization
[99, 100, 48, 101, 102, 103, 104, 105], sample size re-estimation [106, 107, 108, 109,
110], changes to eligibility criteria [3, 111, 112], and early stopping rules for safety,
futility or efficacy [113, 114, 115, 116, 117, 105, 118, 119]. Adaptive randomization
procedures can use a frequentist framework [84, 120, 50] or a Bayesian framework
[121, 122]. Commonly used adaptive randomization methods include treatment-
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adaptive randomization, covariate adjustment randomization and response adaptive
randomization [99, 100, 48, 123, 124, 125, 126, 127]. Bayesian adaptive random-
ization methods allow the combination of prior knowledge and observed data to
learn about parameters of interest [128]. Bayesian adaptive randomization proce-
dures apply Bayes theorem repetitively based on accumulating data to adjust the
randomization probability for each newly enrolled patient. Such procedures may be
considered more ethical by assigning more patients to the more effective treatment
arm. Several clinical trials have adopted Bayesian adaptive randomization, including
BATTLE and I-SPY2 [129, 124, 130, 131, 132, 133, 134, 135, 136, 137, 138].
Recently, the rapid advancement of biomarker studies in oncology has pro-
moted the development and application of precision medicine, previously known as
“personalized medicine” [139, 140]. Precision medicine targets a subpopulation of
patients who are most likely to respond to the treatment based on their character-
istics or biomarker profile. Prognostic biomarkers provide information on clinical
outcome independently of the treatment received, while predictive biomarkers pro-
vide information on clinical outcome for a particular treatment [141]. Prognostic
biomarkers can be used to screen good and bad prognostic patients, while predictive
biomarkers can be used to measure how likely the patient will respond to a particular
treatment. Before using biomarker information in clinical practice, it is essential to
test the biomarkers for analytical and clinical validity and clinical utility [142, 143].
For the designs described in this paper, we focus on predictive biomarkers.
A biomarker adaptive design utilizes patient biomarker information measured
at baseline to allow adaptation based on previous patients’ responses. When the
biomarkers used to categorize the sensitive status for potential patients are known
before the start of the clinical trial, a biomarker adaptive design is particularly useful.
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If the biomarker is unknown, one may consider an adaptive signature design [1] or the
cross-validated variation of this design [2]. These designs use an equal randomization
approach but include a development stage and a validation stage to determine a
sensitive subset classifier. An adaptive enrichment design [3] allows changes to the
enrollment criteria as the trial proceeds. Restricting enrollment to patients who are
most likely to benefit from the treatment based on a classifier improves the efficiency
of the clinical trial but may require a longer time to accrue the targeted patients.
In this chapter, we propose a cross-validated signature enrichment design
with Bayesian response-adaptive randomization. This design combines the elements
of cross-validated adaptive signature designs and adaptive enrichment designs. Dur-
ing patient enrollment, our design uses an enrichment strategy which oversamples
the sensitive patient cohort and undersamples the non-sensitive patients. It also
applies Bayesian response-adaptive randomization, adaptively adjusting future allo-
cation probabilities based on the accumulated data. As a result, this design has the
advantages of Bayesian adaptive randomization as well as an enrichment strategy,
yielding a higher overall response rate on the trial and other advantages described
below and with comparable power to the other two designs. At the end of the trial,
we test the treatment effect in the overall patient group, and in the sensitive patient
subgroup with the control of type I error rates.
In addition to the usual evaluation of statistical power, we propose four trial
evaluation criteria to assess the performance of the designs: current individual loss
(CIL), future individual loss (FIL), the probability of an individual in the trial re-
ceiving optimal treatment (PCO) and the probability of a future individual receiving
personalized optimal treatment (PFO). These criteria evaluate the benefits for both
trial participants and future patients from the perspective of precision medicine, pro-
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viding a more comprehensive assessment of trial performance. Results are demon-
strated in extensive simulations.
The rest of this chapter is organized as follows. In section 2, we briefly
review the cross-validated adaptive signature design with respect to individual pa-
tient criteria, the adaptive enrichment design, and our Bayesian response-adaptive
randomization scheme. In section 3, we describe our cross-validated signature en-
richment design with response-adaptive randomization. In section 4, we define the
trial performance evaluation criteria. In section 5, we report the results of simulation
studies to compare our proposed design with the cross-validated adaptive signature
design and the adaptive enrichment design. In section 6, we present an example
based on the Iressa Pan-Asia Study (IPASS) [144]. In section 7, we conclude with a
brief discussion.
4.2 Review of Adaptive Signature Designs, Adaptive Enrichment De-
signs and Bayesian Adaptive Randomization
As the name suggests, our proposed cross-validated signature enrichment de-
sign combines with Bayesian response-adaptive randomization. In this section, we
briefly review the cross-validated adaptive signature design, the adaptive enrichment
design, and the Bayesian response-adaptive randomization method. For all the de-
signs mentioned in this article, we consider a two-arm clinical trial to compare the
efficacy of an experimental treatment E and a control treatment C.
4.2.1 Adaptive signature design (ASD)
When a reliable classifier for identifying sensitive patients is not available at
the start of the trial, an adaptive signature design [1, 145] may be useful. If the
overall test for treatment effect is not significant, this design defines a development
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stage and a validation stage for a sensitive patient subpopulation classifier. Since
only a portion of patients contributes to each stage, the cross-validated extension of
the adaptive signature design [2] adopts a K-fold cross-validation method to classify
patients from the entire population and to adjust the P value using a permutation
test [146].
As illustrated in Figure 1, this design uses equal randomization and if the
overall test is not significant, divides patients into two cohorts: a development cohort
and a validation cohort for determining a sensitive subset classifier. The design
controls the overall type I error rate at α, where α = α1+α2. If the overall treatment
effect is statistically significant at some pre-specified level α1, then the experimental
treatment is considered globally beneficial. Otherwise, the adaptive signature design
develops a sensitive patient classifier and tests whether the classifier is useful for
treatment selection at type I error rate α2.
The classification of a sensitive patient subgroup is based on machine learning
voting methods in two stages. The first stage identifies predictive biomarkers. The
second stage identifies sensitive patients based on the chosen predictive biomarkers
from stage I. A patient in the validation set is classified as sensitive if the predicted
odds ratio of experimental arm versus standard arm exceeds some pre-specified value.
The treatment effect only in the sensitive patients in the validation cohort is then
assessed at a pre-specified reduced type I error rate α2 to test whether the classifier
is useful for treatment selection.
The cross-validated adaptive signature design utilizes K-fold cross-validation
to obtain a final sensitive patient subset from the entire trial population. Since the
sensitive patient subset is obtained using cross-validation, a permutation test may





















Figure 4.1: Diagram for Adaptive Signature Design (ASD) [1, 2].
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4.2.2 Adaptive enrichment design (AED)
The adaptive enrichment design [3, 147, 148, 149] restricts enrollment to sen-
sitive patients, as defined by an adaptive classifier function, and excludes all nonsen-
sitive patients. Patients are grouped into blocks according to their entry time. For
the initial patient block, equal randomization is used to allocate patients to treat-
ment arms. For subsequent patient blocks, as illustrated in Figure 2, the probability
of response is estimated for patient i with each treatment E and C, based on the
cumulative estimated response rates from patients in the previous blocks. Let r̂i,E
and r̂i,C denote the response rate of patient i when receiving E or C, respectively.
The classifier function determines the sensitive status, which is defined as
(4.1) CF (r̂i,E, r̂i,C) = I(r̂i,E − r̂i,C > δ),
where δ denotes the minimal clinical meaningful difference. Let ĈF i refer to the lat-
est estimate of the classifier function at the time of the entry of the ith patient. The
classifier function restricts entry into the trial to patients with ĈF i = 1, the sensitive
patients, and excludes patients whose ĈF i = 0, the non-sensitive patients. Newly
enrolled patients will be assigned to one of the treatment arms using equal random-
ization. The classifier will be updated once a new block data becomes available. The
process is repeated until the desired total number of patients is reached.
As the adaptive enrichment design will include mostly sensitive patients (ex-
cept in the initial patient block), it can improve the efficiency of the clinical trial
and protect non-sensitive patients from exposure to ineffective treatments. However,
it can be difficult to estimate treatment effect size and choose a strategy to update
enrollment criteria and requires a longer time to accrue sufficient number of sensitive






Figure 4.2: Diagram for Adaptive Enrichment Design (AED) [3]. CF denotes the sensitive status
classifier function.
in all patients, restricting enrollment may exclude patients who would benefite from
participating in the trial [150, 4, 5].
4.2.3 Bayesian adaptive randomization
Bayesian adaptive randomization updates allocation probabilities based on
currently enrolled patient responses, assigning more patients to the more effective
treatments. Compared with equal randomization, response-adaptive randomization
places more emphasis on individual benefit and advantages, especially with compli-
cated designs [53, 81]. Some objections to adaptive randomization include potential
bias due to inhomogeneous patient population throughout the trial, statistical inef-
ficiency due to unbalanced patient allocation and the requirement that responses be
collected shortly after treatment [5, 151, 152, 90, 153]. Generally, the advantages of
response-adaptive randomization are more evident with larger sample sizes and with
larger differences between treatments.
Bayesian adaptive randomization assumes that the allocation probability for
treatment E is proportional to the posterior probability P̂ (r(i, E) > r(i, C)|data).
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The probability of patient i receiving treatment E, Pi,E, is given by [80, 154, 79] as
(4.2) Pi,E =
P̂ (r(i, E) > r(i, C)|data)w
P̂ (r(i, E) > r(i, C)|data)w + P̂ (r(i, E) ≤ r(i, C)|data)w
where w is a tuning parameter between 0 and 1. When w is equal to 0, there is equal
randomization. When w is equal to 1, Pi,E is the same as P̂ (r(i, E) > r(i, C)|data).
Common practice is to set w equal to 1/2 or to use n/2N where n is the cumulative
sample size [80].
4.3 Signature Enrichment Design with Adaptive Randomization (SEDAR)
We propose a cross-validated signature enrichment design with response-
adaptive randomization. For the initial block, we use equal randomization and let the
initial block size be twice that of the subsequent adaptive randomization blocks [155].
The framework for subsequent patient blocks of the design is presented in Figure 3.
We assume patient responses can be observed shortly after receiving treatments. The
enrollment procedure for future patients is as follows:
1. For each patient, apply the current sensitive patients classifier function (CF)
derived on data from previous blocks. This separates patients into one of the
two categories: sensitive and non-sensitive.
2. If the patient is determined to be sensitive, randomize to E or C based on the
Bayesian adaptive randomization scheme.
3. If the patient is determined to be non-sensitive, calculate the enrollment function
(EF = 1 with probability P ; EF=0 with probability 1-P). If EF=1, randomize
based on the Bayesian randomization scheme as above; if EF = 0, the patient
is off study (i.e., not randomized). The details of determining the enrollment














Figure 4.3: Diagram for Signature Enrichment Design with Adaptive Randomization (SEDAR).
CF is the classifier for determining patient sensitive status; EF is the enrollment function; Pi is
the probability of enrolling the ith patient.
4. After the current block is completely accrued, refine the classifier function based
on the additional results from the current block and repeat the steps above for
the next block.
As is common with all enrichment designs, it is difficult to calculate the
required sample size a priori. To estimate the total required sample size for our
design, we first calculate the sufficient sample size to reach the desired power using
traditional methods for non-enrichment designs [156, 157]. Then we use simulations
to modify the sample size for the given design parameters.
4.3.1 Sensitive-patient classifier function and enrollment function
After each block of data becomes available, we develop a sensitive patient
classifier to screen for future patients. Many classification algorithms have been
studied for biomarker classifier development [158, 159, 160, 161, 142]. Some popular
choices include logistic regression, random forest [162], support vector machines [163]
and diagonal linear discriminant analysis [164]. To estimate the probabilities of
response for a patient with the experimental or control treatment, many statistical
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models or algorithmic methods, e.g., logistic regression and random forests, may be
used [165, 166]. For our proposed design, we use a random forest approach. In
practice, a different classification algorithm may be used depending on trial-specific
consideration. A brief description of the random forest technique is summarized
below. More details can be found elsewhere [162, 167].
Random forests grow a large collection of de-correlated decision trees [168].
Each tree starts with drawing a bootstrap sample from the original dataset. At each
node, a best split is determined among a randomly selected subset of the total input
variables. When a random forests approach is used for classification purpose, the
class prediction is the majority vote from the total number of decision trees. The
class probabilities are the proportion of votes from the ensemble of trees.
At an early stage of the clinical trial, the available patient data to build a
classifier is limited. In contrast to the adaptive enrichment designs that restrict entry
into the trial to sensitive patients, we use an enrichment strategy which will include
both sensitive and non-sensitive patients but with different enrollment probabilities.
Let δ denote the minimal clinical meaningful difference and r̂i,x,E and r̂i,x,C denote
the estimated response rates for potential patient i with signatures x if receiving
treatment E or C, respectively. The sensitive patient status is determined in the
same way as AED, which is:
(4.3) CF (r̂i,E, r̂i,C) = I(r̂i,x,E − r̂i,x,C > δ),
Let ĈF i refer to the latest estimate of the classifier function at the time of entry of
the ith patient. If ĈF i = 1, then patient i is sensitive; otherwise, the patient i is non-
sensitive. For sensitive patients, the probability of enrollment is 1. For non-sensitive
patients, we use a continuous function as the enrollment function to determine the
enrollment probability for patient i with signatures x. The enrollment probabilities
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are calculated as




Thus, the probability for sensitive patients is 1 (i.e., all sensitive patients are enrolled)
and for non-sensitive patients the enrollment probability is between 0.1 and 1. When
all patient data are available, we build a final sensitive patient subset classifier. In
our design, we use random forests as the algorithm for sensitive status classification.
During the trial process, we screen sensitive patients to enroll in the next
block. This sensitive patient classifier is built on the previous patient response,
treatment received and biomarker information. At the final analysis, the classifier
is developed by cross-validation based on complete patient data, as described in the
next subsection. The sensitive patient subset selected is used to test the treatment
effect difference in the sensitive subgroup.
4.3.2 Bayesian decision rule
For the proposed design, we estimate the power to detect the difference of the
treatment effect between E and C in the overall patient group and in the sensitive
patient subset using Bayesian decision rules.
To test the treatment effect in the sensitive population, we first identify the
overall sensitive patient subset from the entire trial population using 10-fold cross-
validation. This technique is also used in the cross-validated extension of the adaptive
signature design [2]. For K-fold cross-validation, the entire trial population is ran-
domly partitioned into K nonoverlapping equal-sized subpopulations. In the final
analysis, one of the K folds is used as the validation cohort, and the rest K− 1 folds
are treated as the development cohort and a sensitive patient subset Sk (k = 1, ..., K)
is developed. This procedure is repeated K times. Each patient appears once in the
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validation cohort and K−1 times in the development cohort. Then the total number
of the sensitive patient subset from the entire trial patients is S =
⋃K
k=1 Sk.
At final analysis, arm E is claim efficacious if
(4.5) P̂ r(rE > rc | data) > aU
where aU is a cut-off parameter whose value is tuned to control the type I error rates.
The type I error rate for testing treatment effect in the overall patient group is α1,
and for testing treatment effect in the sensitive subset it is α2, so that the overall
type I error rate α = α1 +α2. That is, we calibrate different aU values for the overall
analysis and for the sensitive subset analysis to control their type I error rates.
4.3.3 Required design parameters
The required design parameters (Table 4.1) are the sample size for the initial
equal randomization block (N0) and for the adaptive randomization blocks (Nbar).
Then the total sample size N = N0 + m ∗Nbar, where m + 1 is the total number of
blocks. Additionally, the proposed design requires one to specify the tuning parame-
ter w; minimal clinical difference δ for sensitive status classification; the type I error
rate for testing the overall treatment effect (α1) and the type I error rate for testing
treatment effect in the sensitive subset (α2).
Table 4.1: Design parameters required for SEDAR.
N0 Sample size for the initial equal randomization block
Nbar Sample size for adaptive randomization blocks
N Total sample size
w Tuning parameter
δ Minimal clinical difference for sensitive status classification
α1 Type I error rate for testing treatment effect in overall patient group
α2 Type I error rate for testing treatment effect in sensitive subset
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4.4 Trial performance evaluation criteria for simulations
In addition to commonly used operating characteristics such as the average re-
sponse rate and power, we propose the following trial performance evaluation criteria
for simulation studies of a signature clinical trial:
• Current individual loss (CIL)
• Future individual loss (FIL)
• Probability of a current individual in the trial receiving personalized optimal
treatment (PCO)
• Probability of a future individual receiving personalized optimal treatment (PFO)
For CIL and FIL, we first define a match for enrolled and future patients.
For currently enrolled patients, a match occurs when the patient’s actual treatment
received is the same as the best treatment from the true model. For future patients,
a match occurs when the superior treatment selected based on the final fitted model
is the same as the best treatment from the true model. For a currently enrolled
patient i with signature x, let P̂i(Y = 1|T, x) denote the probability of responding
to the received treatment T . Similarly, for a potential future patient, P̂i(Y = 1|T, x)
refers to the probability of responding to treatment T as determined by the fitted
model. Let P̂i(Y = 1|T = OPT, x) denote the probability of responding to the
optimal treatment determined by the true model. Then we define the personalized




0 if it is a match
P̂i(Y = 1|T, x)− P̂i(Y = 1|T = OPT, x) if there is not a match
Then CIL and FIL are the average values of the individual loss for trial partic-
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ipants and for future patients, respectively. A small value of CIL indicates that most
currently enrolled patients have received the treatment that they will respond at least
similarly as the optimal treatments according to the true model. The interpretation
is similar for FIL.
The PCO and PFO quantities are the probabilities of receiving the personal-
ized optimal treatment for trial participants and future patients, respectively. PCO
can be estimated as the average fraction of matches between the optimal treatment
selection by the true model and by the patients’ actual treatment received.
PFO is the probability of a future patient receiving the personalized optimal
treatment if the treatment recommendation from the trial were followed. It can be
estimated as the average fraction of matches for prospective patients between the
optimal treatment selections by the true model and by the final fitted model. A
large value in PCO and PFO indicates that most patients have received and will
receive their optimal treatments determined by the true model, respectively.
The main differences between CIL & FIL and PCO & PFO are that for CIL
and FIL, the penalties for non-matches depend on the individual loss; for PCO and
PFO, all non-matches receive the same penalty. Small values of CIL and FIL, and
large values of PCO and PFO are desirable.
4.5 Simulation Studies
We performed a series of simulations to evaluate our design and compared it
with the adaptive signature design and the adaptive enrichment design. For all the
designs, we implemented the cross-validated procedures to search for final sensitive
subsets from the entire patient population. To make ASD and AED comparable to
SEDAR, all the designs used the Bayesian decision rules described above at final
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analyses.
We assume a two-treatment clinical trial designed to compare a control treat-
ment (C ) with an experimental treatment (E ). We include situations where the




0.5 Treatment = E
−0.5 Treatment = C
, i = 1, · · · , n.
4.5.1 Simulation setting
The total sample size N is set at 300; the size of the adaptive randomization
blocks Nbar is set at 50. We choose the size N0 of the initial block, for which equal
randomization is used, to be N0 = 100. Hence, we have a total of 5 blocks of sizes
100, 50, 50, 50 and 50. The tuning parameter for Bayesian adaptive randomization
w is set at 0.5. The minimal clinical meaningful difference for sensitive patient status
qualification is set at 0.1. The type I error rate α1 for testing overall treatment effect
is controlled at 0.04, and the type I error rate α2 for testing treatment effect in the
sensitive subset is controlled at 0.01.
We generate the ith patient’s response from the following logistic regression
model with ten biomarkers:






ηkTiXki, i = 1, · · · , 300; k = 1, · · · , 10.
where Xki is the k
th biomarker/signature for patient i. Each biomarker Xki is as-
sumed to follow a normal/multivariate normal distribution with mean of 0.5 and
standard deviation of 1.0.
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For the Bayesian adaptive randomization, we assume the prior is
β0, β1, γk, ηk ∼ Normal(µ = 0, σ2 = 100).
At the final analysis, for each treatment arm, we use a non-informative prior
Beta(1, 1).
We consider three categories of biomarker distributions. For each type, we
include four scenarios and a null scenario to compare the performance of SEDAR
with ASD and AED (Table 4.2). The biomarker or biomarker-treatment interaction
effects not presented in the table are assumed to be zero.
For the first category, we assume all biomarkers are independently distributed
following a normal distribution with mean 0.5 and variance 1.0. For scenarios 1 and 2,
we consider only X1 and the corresponding treatment interaction affect the response
with different magnitude. For scenarios 3 and 4, we assume X1 and X6, and their
interactions with treatment will affect the patient response with different scales.
For the second category, we assume the first five biomarkers have a multi-
variate normal distribution X ∼ NVM(0.5,Σ) with covariance matrix which has
1 for the variance and 0.25 for ρ. The other five variables are still independently
distributed with a normal distribution with mean 0.5 and variance 1.0. For scenarios
7 and 8, we consider only X1 and the corresponding treatment interaction affect
the response. For scenarios 9 and 10, we assume one biomarker from the first five
correlated biomarkers, X1 and its interaction with treatment and another biomarker
from the independent biomarker group, X6 and its interaction with treatment, affect
the response.
For the third category, we assume the first five biomarkers have a multivariate
normal distribution with mean 0.5 and covariance matrix with ρ = 0.75, and the
remaining five biomarkers have a multivariate normal distribution with mean 0.5
48
Table 4.2: Simulation scenarios
β0 β1 γ1 η1 γ6 η6
x1 to x10 are continuous with ρ = 0.00 Scenario 1 -0.8 0.0 0.0 0.0 0.0 0.0
Scenario 2 -0.8 0.0 0.8 0.8 0.0 0.0
Scenario 3 -0.8 0.0 0.3 1.1 0.0 0.0
Scenario 4 -0.8 0.0 0.3 0.3 0.7 0.7
Scenario 5 -0.8 0.0 0.4 0.4 1.1 1.1
x1 to x5 are continuous with ρ = 0.25 Scenario 6 -0.8 0.0 0.0 0.0 0.0 0.0
x6 to x10 are continuous with ρ = 0.00 Scenario 7 -0.8 0.0 0.8 0.8 0.0 0.0
Scenario 8 -0.8 0.0 0.3 1.1 0.0 0.0
Scenario 9 -0.8 0.0 0.3 0.3 0.7 0.7
Scenario 10 -0.8 0.0 0.4 0.4 1.1 1.1
x1 to x5 are continuous with ρ = 0.75 Scenario 11 -0.8 0.0 0.0 0.0 0.0 0.0
x6 to x10 are continuous with ρ = 0.25 Scenario 12 -0.8 0.0 0.8 0.8 0.0 0.0
Scenario 13 -0.8 0.0 0.3 1.1 0.0 0.0
Scenario 14 -0.8 0.0 0.3 0.3 0.7 0.7
Scenario 15 -0.8 0.0 0.4 0.4 1.1 1.1
and covariance matrix with ρ = 0.25. The simulation scenarios are similar to the
other two categories.
All the categories and scenarios are listed in Table 4.2. The null scenarios for
each category numbers 1, 6 and 11, respectively. For each scenario, we generated
5,000 simulations.
4.5.2 Simulation results
We compare the results obtained using our proposed design with those ob-
tained using ASD and AED. The results for the estimated power are presented in
Table 4.3. The type I error rates for the treatment effect in the overall patient group
and the sensitive subgroup are controlled at 0.04 and 0.01, respectively.
For the rest scenarios, ASD always has the lowest power, while AED or
SEDAR has the highest power. In scenario 3, 8, 13, AED has a higher power
than SEDAR. For example, in scenario 3, the power in the overall patient group
for ASD, AED and SEDAR are 0.750, 0.987 and 0.964, respectively. In the sensitive
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subgroup, the power is 0.721 for ASD, 0.920 for AED and 0.823 for SEDAR. For
the other scenarios, SEDAR achieves the highest power in both overall group and
sensitive subset. For scenario 7, the power in the overall patient group is 0.539 for
ASD, 0.830 for AED and 0.892 for SEDAR.
The results of the four trial performance evaluation criteria we proposed in
section 4 are presented in Table 4.3. While both ASD and AED adopt an equal
randomization approach when assigning patients to treatment arm, resulting in equal
numbers of patients per treatment arm, SEDAR assigns more patients to the superior
treatment based on baseline biomarker profiles and data accumulation during the
trial. As a result, SEDAR always achieves a higher objective response rate (ORR)
than ASD and AED. For example, in scenario 15, 55.6% of patients respond to the
assigned treatment for SEDAR compared to 47.7% for ASD and 53.7% for AED. AED
results in a higher proportion of patients who respond to the assigned treatment than
ASD. This demonstrates that the enrichment strategy allows more trial participants
to achieve responses than the all-comers designs.
Table 4.3: Overall analysis: operational characteristics
SCEN Parameters Design Ovl Sens ORR CIL FIL PCO PFO
Power Power
1 NULL ASD 0.010 0.010 0.010 0.310 0.000 1.000 1.000
AED 0.037 0.010 0.011 0.310 0.000 1.000 1.000
SEDAR 0.038 0.011 0.008 0.310 0.000 1.000 1.000
2 γ1 = η1 = 0.8 ASD 0.510 0.300 0.410 0.073 0.031 0.501 0.715
AED 0.815 0.560 0.461 0.088 0.014 0.500 0.902
SEDAR 0.888 0.577 0.466 0.057 0.033 0.606 0.695
3 γ1 = 0.3 ASD 0.744 0.721 0.353 0.107 0.023 0.500 0.766
η1 = 1.1 AED 0.987 0.920 0.374 0.127 0.009 0.500 0.909
SEDAR 0.968 0.823 0.414 0.072 0.024 0.637 0.751
4 γ1 = η1 = 0.3 ASD 0.635 0.348 0.430 0.077 0.032 0.500 0.723
γ6 = η6 = 0.7 AED 0.854 0.590 0.472 0.090 0.014 0.500 0.911
SEDAR 0.911 0.614 0.483 0.059 0.034 0.610 0.701




SCEN Parameters Design Ovl Sens ORR CIL FIL PCO PFO
Power Power
γ6 = η6 = 1.1 AED 0.964 0.833 0.537 0.111 0.012 0.500 0.927
SEDAR 0.993 0.892 0.557 0.067 0.030 0.639 0.760
6 NULL ASD 0.040 0.008 0.310 0.000 0.000 1.000 1.000
AED 0.040 0.008 0.310 0.000 0.000 1.000 1.000
SEDAR 0.040 0.010 0.310 0.000 0.000 1.000 1.000
7 γ1 = η1 = 0.8 ASD 0.523 0.327 0.410 0.073 0.031 0.501 0.718
AED 0.807 0.587 0.463 0.088 0.013 0.499 0.908
SEDAR 0.894 0.594 0.468 0.057 0.033 0.607 0.697
8 γ1 = 0.3 ASD 0.744 0.693 0.353 0.107 0.023 0.500 0.767
η1 = 1.1 AED 0.990 0.931 0.377 0.128 0.009 0.500 0.917
SEDAR 0.974 0.842 0.415 0.073 0.024 0.636 0.752
9 γ1 = η1 = 0.3 ASD 0.653 0.362 0.430 0.077 0.032 0.500 0.725
γ6 = η6 = 0.7 AED 0.855 0.587 0.471 0.090 0.014 0.500 0.911
SEDAR 0.917 0.638 0.482 0.058 0.034 0.612 0.706
10 γ1 = η1 = 0.4 ASD 0.808 0.615 0.478 0.097 0.028 0.501 0.771
γ6 = η6 = 1.1 AED 0.971 0.826 0.537 0.111 0.013 0.500 0.926
SEDAR 0.991 0.895 0.555 0.068 0.030 0.637 0.756
11 NULL ASD 0.037 0.010 0.310 0.000 0.000 1.000 1.000
AED 0.039 0.010 0.310 0.000 0.000 1.000 1.000
SEDAR 0.038 0.009 0.310 0.000 0.000 1.000 1.000
12 γ1 = η1 = 0.8 ASD 0.514 0.329 0.412 0.073 0.029 0.500 0.732
AED 0.851 0.625 0.468 0.090 0.010 0.500 0.922
SEDAR 0.898 0.620 0.473 0.058 0.031 0.608 0.708
13 γ1 = 0.3 ASD 0.737 0.729 0.353 0.107 0.022 0.501 0.785
η1 = 1.1 AED 0.992 0.945 0.379 0.131 0.007 0.500 0.938
SEDAR 0.980 0.885 0.419 0.074 0.024 0.640 0.768
14 γ1 = η1 = 0.3 ASD 0.637 0.351 0.428 0.077 0.032 0.500 0.723
γ6 = η6 = 0.7 AED 0.852 0.585 0.472 0.090 0.013 0.500 0.914
SEDAR 0.909 0.631 0.485 0.059 0.035 0.610 0.696
15 γ1 = η1 = 0.4 ASD 0.798 0.606 0.478 0.097 0.029 0.501 0.770
γ6 = η6 = 1.1 AED 0.972 0.849 0.539 0.112 0.012 0.500 0.928
SEDAR 0.991 0.880 0.557 0.068 0.031 0.639 0.753
CIL and FIL measure the loss for trial participants and future patients. ASD
and AED have similar values of CIL, while SEDAR has much smaller values than the
other designs. Using scenario 5 as an example, CIL for SEDAR is 0.067 compared
to 0.097 for ASD and 0.111 for AED. This difference in CIL shows that SEDAR
results in more trial participants receiving optimal treatments. For FIL, the results
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are similar for ASD and SEDAR, but AED has the smallest values in all scenarios.
This show that a complete enrichment strategy may allow more future patients to
receive their optimal treatments.
SEDAR also has higher PCO values than the other designs. That is, SEDAR
results in a higher proportion of enrolled patients receiving their optimal treatments
as defined by the true model. Similar to the relative performance among the three
designs, SEDAR and ASD show similar results for PFO, which refers to the probabil-
ity for a future patient receiving the personalized optimal treatment if the treatment
recommendation from the trial were followed.
The results for true and the estimated treatment effect for the entire trial
patient population and for sensitive patient subset are presented in the supplemental
materials. The results show that the difference of the average response rate among
all patients in a trial between E and C mainly determines the power of a trial.
The results of the proportion of truly sensitive patients in the overall patient group
and in the sensitive patient subset are also included in the supplemental materials.
According to the results, AED trials have the highest proportion of truly sensitive
patients, following by SEDAR and ASD, demonstrating that enrichment strategies
include more patients who are likely to respond to the treatment than all comers
designs, one of the key reasons for considering enrichment designs.
4.6 Example
To illustrate our approach, consider the design of a trial in non-small-cell
lung cancer (NSCLC) comparing two treatment arms, one using a tyrosine kinase
inhibitor (gefitinib) and the other using standard chemotherapy (carboplatin plus
paclitaxel), similar to the Iressa Pan-Asia Study (IPASS)[144]. The single binary
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biomarker in this case is the EGFR mutation status, either positive or negative,
with a prevalence of EGFR positive patients of approximately 50% in Asian countries
and approximately 20% in North America [169]. For the purpose of illustrating the
application in the setting of this paper (binary response assessed soon after the start
of treatment), we consider the endpoint to be objective response rate. Unfortunately,
since the assessment of EGFR mutation status was not an eligibility requirement,
only 36% of the patients (437 of 1217) had a known status. To conduct simulations
using the IPASS study as a guide, we assume the prevalence of EGFR+ to be 0.50
(commonly observed in an Asian population) and the following response rates in
the various treatment arms and EGFR mutation status groups (no missing values):
0.45 in the EGFR positive chemotherapy arm; 0.70 in the EGFR positive gefitinib
arm; 0.15 in the EGFR negative chemotherapy arm; and 0.10 in the EGFR negative
gefitinib arm.
Although this example is presented as an illustration of the setting considered
here, the final endpoints in such a study would ordinarily be overall progression-free
survival (PFS) or overall survival (OS), not the response rates. In the initial results
reported for the IPASS study, there was improved PFS for gefitinib in the EGFR
mutation-positive group but worse PFS for gefitinib in the EGFR mutation-negative
group. These overall results are suggested in the early results, but not definitively so
except perhaps in the EGFR negative group because of the dramatic early difference.
To apply our design to the IPASS study, we assume a total sample size of 440;
an initial block size of 176 patients, and subsequent adaptive randomization block
size of 88 patients. The overall type I error rate is controlled at 0.05 with 0.04 for
the global treatment effect test and 0.01 for the sensitive subset test. The clinical
meaningful difference for enrolling sensitive patients is set at 0.1.
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Following the approach used in the IPASS paper for progression-free survival
[144], we use the following covariates in a logistic regression model for ORR, all as
binary covariates: Age (< 65 years vs. ≥ 65 years), Sex (Male, Female), Smoking
history (non-smoker vs. former light smoker), WHO performance status (0 or 1 vs.
2). We assume only the EGFR mutation status and its interaction have a treatment
effect. In the true model, no treatment main effect is included. The prevalence of
each biomarker stratum is presented in Table 4.4.
Table 4.4: IPASS example: biomarker settings
Biomarkers Gefitinib Chemotherapy
EGFR status
EGFR + 0.50 0.50
EGFR - 0.50 0.50
Age
< 65 years 0.72 0.76






Former light smoker 0.062 0.064
WHO performance status
0 or 1 0.90 0.89
2 0.10 0.11
For the given design parameters, the results are presented in Table 4.5. Gen-
erally, the results confirm the conclusion drawn from the previous simulation studies.
The power of the overall population is 0.738 for ASD; 0.995 for AED; and 0.999 for
SEDAR, and of the sensitive subset is 0.946 for ASD, 0.993 for AED and 0.982 for
SEDAR. The objective response rates among all trial participants are 0.361 by ASD;
0.442 by AED; and 0.446 by SEDAR. In addition, SEDAR also has the lowest CIL
index and high values for PCO. Thus, our proposed design can assign more patients
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to receive their optimal treatments.
Table 4.5: Simulation results: IPASS example
Design Ovl Power Sens Power ORR CIL FIL PCO PFO
ASD 0.738 0.946 0.361 0.096 0.089 0.501 0.605
AED 0.995 0.993 0.442 0.121 0.035 0.449 0.838
SEDAR 0.999 0.982 0.446 0.063 0.051 0.662 0.768
4.7 Discussion
In this article, we have proposed a cross-validated signature enrichment design
with adaptive randomization for cancer clinical trials. Our proposed design builds on
the advantages of the adaptive signature design and the adaptive enrichment design.
Assuming that patient responses can be observed shortly after receiving treatment,
our design adopts an adaptive enrichment approach by developing a sensitive pa-
tient classifier to screen sensitive and non-sensitive patients for enrollment. Once a
patient enters the trial, we use response-adaptive randomization to adjust treatment
allocation probabilities in a Bayesian framework. At the final analysis, we use an
adaptation of the adaptive signature designs. For the sensitive patient subset test,
this design efficiently identifies sensitive patients from the entire trial participant
population using a cross-validated procedure.
Our results have shown that ASD always has the lowest power, while SEDAR
has the highest power in most scenarios. The main difference between AED or
SEDAR and ASD is that both AED and SEDAR are “enrichment” designs, they
enrolling more “sensitive” patients than ASD, which enrolls all patients.
To help clarify the relative performance of power between AED and SEDAR,
denote by r|E the response rate among all patients in a trial who receive the experi-
mental treatment (E), and r|C the response rate among those who receive the control
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treatment (C). The main reason the power of SEDAR is consistently higher than that
of AED in our simulation scenarios is that r|E − r|C is larger in the SEDAR trials
than in the AED trials. This is caused by the covariate-based outcome-adaptive
randomization adopted by SEDAR. A toy example is given below.
Suppose the population consists of two groups of patients: 2/3 sensitive and
1/3 non-sensitive. For sensitive patients, the response rates by E and C are 0.6
and 0.3 respectively. For non-sensitive patients, the response rate is 0.3 regardless
of treatment. Assume the total sample size is 300, and by the AED design, 80
non-sensitive patients and 220 sensitive patients are enrolled. Due to the equal
randomization, among each group (sensitive or non-sensitive), 50% patients have
received E, and 50% received C. Then in this setting, r|E = 0.52, r|C = 0.30, thus
r|E − r|C = 0.22.
For SEDAR, assume 100 non-sensitive and 200 sensitive patients are enrolled.
By SEDAR, non-sensitive patients are equally randomized between E and C, whereas
sensitive patients are more likely to be assigned to E. Assume 80% of sensitive
patients have received E, and 20% received C. In this setting, r|E = 0.54, r|C =
0.30, thus r|E − r|C = 0.24. SEDAR results in a higher value of r|E − r|C than
AED, thus higher power.
For clinical trials that do not consider patients’ biomarkers X or in which
the biomarker is not predictive, the underlying assumption is that all patients are
homogeneous and the patient heterogeneity is ignored. In this situation, it is true
that, when compared with equal randomization, adaptive randomization will lose
power with some exceptions (e.g., some scenarios with binary outcomes). However,
in this paper, we account for patient heterogeneity and use regression models of
response on X to predict future patients response rates to E or C. Although both
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AED and SEDAR use these results to select patients to enroll, only SEDAR uses
these results to adjust patients’ probability to receive E or C. The consequence is
that, as seen from above, SEDAR trials have larger values of r|E − r|C, and thus
higher power levels than AED.
Another feature in our designs affects the power. In the simulations, for AED
and SEDAR, we have used slightly different enrollment functions for non-sensitive
patients. While AED gives a zero chance for non-sensitive patients to enroll, SEDAR
gives a chance between 0.1 and 1 for them. This difference favors AED for power
(i.e., should make AED have higher power than SEDAR). The final power is the
combined effect of this enrollment function and the above effect on r|E− r|C caused
by the adaptive randomization.
Our results have also shown that adopting an enrichment strategy - oversam-
pling the sensitive patients and undersampling the nonsensitive patients will offer
benefits to trial participants. This is particularly important for late-stage cancer
patients since many will need to enroll in clinical trials to have access to novel treat-
ments. The enrichment strategy described here can be applied to other biomarker
adaptive designs [170, 157, 140, 171]. For example, the recently-proposed enriched
biomarker stratified design and the auxiliary-variable-enriched biomarker stratified
design also show that applying an enrichment strategy can result in a more cost-
efficient design in terms of power [111, 112]. For both of these designs, the issue
is how to choose the optimal enrichment proportion. Our proposed design uses a
continuous loss function based on the response rate estimates for each treatment for
a given patient using a classification algorithm. In addition to using an enrichment
strategy to increase trial efficiency, our proposed design also utilizes Bayesian adap-
tive randomization approach to sequentially update treatment assignment probabil-
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ities based on patients’ biomarker signatures measured at baseline. The simulation
results imply that our design has more promising trial operating characteristics in
most scenarios.
To address the personalized aspect of precision medicine, we also proposed
four trial performance evaluation criteria in addition to the traditional operating
characteristics. The criteria include CIL, FIL, PCO and PFO for both currently
enrolled patients and future patients. These criteria numerically present how well
the trial design will offer patients their own personalized optimal treatment.
Although our design has distinct advantages, there are some caveats. The
complexity of utilizing an enrichment strategy as well as a Bayesian adaptive ran-
domization scheme, yields operational complexities. In addition, in common with
other types of adaptive enrichment trials, there is a potential for the trial duration
to increase and raise issues of interpretation of the final tests and treatment effect
estimates arising from the adaptive enrichment process.
Compared to the all-comers, equal randomization designs, one limitation of
an adaptive enrichment strategy is that the final sensitive subset may not represent
the true subgroup in the real world. However, if the true proportions of patients
in the various subcategories were known, one could reconstruct the “real world”
setting by post-hoc weighting to give some idea of the potential bias. Our proposed
design allows more patients to receive optimal personalized treatments, thus yielding
a higher overall response rate on the trial. This design can identify therapies that
are globally beneficial as well as treatments that are effective only in a sensitive
subset. The proposed cross-validated signature enrichment design with adaptive




A Signature Enrichment Design with Bayesian Adaptive
Randomization for Umbrella Trials
5.1 Introduction
Traditional “one-size-fits-all” cancer trial assumes all patients are homoge-
neous. However, in the modern era of cancer research, tumor molecular profiles
are now better understood. This advent of precision medicine promotes a shift in
treatment development from “one-size-fits-all” to biomarker-driven therapies that
are tailored based on each patient’s biomarker profile [172, 173, 25]. Novel clinical
trial designs are needed to answer more clinical questions more efficiently and in less
time.
A master protocol is one overarching protocol which allows simultaneous eval-
uation of multiple treatments or disease population in multiple sub-studies [88, 174,
175, 32]. Based on the characteristics, a master protocol is categorized into three
types: basket, umbrella, and platform trials. Each type includes one or more com-
ponents that are more efficient than running a single trial.
Basket trials evaluate single treatment within a biomarker positive subgroup
but for multiple histologies. The goal is to identify unambiguous signals of treatment
based on molecular features rather than histology [32, 33, 176]. Basket trials are
usually early phase, single-arm studies, and only need to develop one assay. They
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are more efficient than separate studies and are particularly useful to test if an already
approved treatment can work on other disease indications. However, the choice of
endpoints may be limited due to prognostic heterogeneity across disease types. It
can also be challenging to define historical controls across different diseases.
Platform trial refers to a randomized trial design with multiple experimental
arms but shares a common control arm. One of the critical features of the platform
trials is the flexibility that allows treatments to enter or exit during the course of
the trial [32, 33, 176]. New treatment can be added, and existing ones can be
declared for superiority or dropped early due to futility, often based on some Bayesian
decision rule throughout a study. The Bayesian hierarchical model is commonly
used to model the various treatment effects by using independent parameters across
subtypes. Adaptive randomization can also be used to allocate more patients to the
most promising arm based on the accumulated data [51, 52].
Different from basket and platform trials, umbrella trials target single histol-
ogy but evaluate multiple treatments each match to a biomarker. Since all patients
are from the same tumor group, any observed benefits can be directly linked to the
biomarker [33, 176]. Umbrella trials are generally mid-to-late phase studies aiming
to identify large treatment effects within a single disease type [176]. Umbrella trials
are flexible, new treatment arm can be added in the process, and inferior arms can
also be terminated early. Umbrella trials also have limitations: it usually requires
a longer duration and larger sample size[176]. The enrollment can be difficult when
the prevalence of a biomarker is low [33, 176]. Umbrella trials can also be combined
with the basket trials to open to multiple histologies.
In this chapter, we aim to extend the Signature Enrichment Design with
Bayesian Adaptive Randomization (SEDAR) to a multi-arm setting, which is suitable
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for umbrella trials. The rest of the paper is organized as follows. In section 2, we
briefly review the umbrella trial design with examples. In section 3, we describe
our signature enrichment design with Bayesian adaptive randomization for umbrella
trials. In section 4, we present the results of simulation studies to compare our
proposed design with the adaptive signature design and the adaptive enrichment
design. In section 5, we conclude with a summary.
5.2 Review of Umbrella Trials
Umbrella trials evaluate multiple treatments within a single disease group. To
determine a patient’s eligibility, a multiplex assay is used, and only biomarker positive
patients will be enrolled. The diagram for umbrella trials is in Figure 5.1. After
screening, patients will be assigned to a sub-study based on their molecular makeup.
Each sub-study has its own treatment targeting the corresponding molecular agents.
For scenarios in which a patient is eligible for multiple arms, inference and hypothesis
testing should be used to account for the overlap. In this section, we review three
on-going or recent umbrella trials: LUNG-MAP, ALCHEMIST, and FOCUS4.
5.2.1 Examples
Lung-MAP
The Lung Cancer Master Protocol (Lung-MAP) is the first precision medicine
trial for patients with previously treated advanced non-small cell lung cancer from
the National Cancer Institute [177, 178]. It is an umbrella study in which the pa-
tient treatment sub-study assignment is based on her/his biomarkers. If a patient
has biomarkers that are targeted by one of the treatments studied in the trial, then
he/she will be enrolled in the corresponding sub-study. For patients with multiple
matched biomarkers, they will be randomized to a cohort using a weighted algorithm
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Single Tumor Type
Biomarker A+ Biomarker B+ Biomarker C+
Treatment A Treatment B Treatment C
Figure 5.1: General Schema for Umbrella Trials.
with a priority given to low prevalence biomarker cohorts. For non-matched patients,
they will be assigned to the non-match group to receive immunotherapy drug com-
binations. Each treatment sub-study can close after enough number of patients have
enrolled. New treatments can be added, and treatments can be dropped from the
trial.
The Lung-MAP trial is a phase II/III trial [179]. The endpoint for the phase
II study is progression-free-survival, and for the phase III endpoint is progression-
free-survival and overall survival. The phase II patients will contribute to the phase
III study if the progression-free survival exceeds an efficacy boundary. In October
2017, 1,400 patients registered. One initial cohort - c-MET-positive was terminated
early due to toxicity [179]. In March 2015, the FDA approved nivolumab in the
same patient population [180]. As a result, the initial control treatment, docetaxel,
is no longer the standard of care. This promotes the Lung-MAP to re-open for
modifications: phase II trials no longer have a control treatment and now become
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single arm with only experimental treatment [176].
ALCHEMIST
The Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing
Trials (ALCHEMIST) is an umbrella trial for patients with early-stage non-small
cell lung cancer (NSCLC) whose tumors have been completely removed by surgery
[181, 182]. The ALCHEMIST trials aim to test if adding erlotinib, crizotinib, or
nivolumab can prolong overall survival for NSCLC patients who have completed
standard therapy.
The ALCHEMIST trials include a screening trial and 3 phase III adjuvant tri-
als: ALCHEMIST-Screening, ALCHEMIST-EGFR, ALCHEMIST-ALK, and ALCHEMIST-
Immunotherapy. The ALCHEMIST-Screening trials exam the patients’ EGFR and
the ALK molecular profiles. For patients who test positive for the EGFR mutation,
they will be enrolled in the ALCHEMIST-EGFR trial to be randomly assigned er-
lotinib or placebo. For patients who test positive for the ALK rearrangement, they
will be enrolled in the ALCHEMIST-ALK trial to be randomly assigned crizotinib or
placebo. For patients who test negative for neither mutations, they may be enrolled
in an ALCHEMIST trial that compares an immunotherapy drug, nivolumab, with
observation. The nivolumab is a checkpoint inhibitor that blocks programmed cell
death protein 1 (PD-1) to allow T-cells attack cancer cells.
The ALCHEMIST trials aim to screen at least 8,000 patients. All patients
screened will be monitored for five years. For the ALCHEMIST-EGFR and the
ALCHEMIST-ALK trials, patients will be assigned to receive the experimental treat-
ment or placebo for two years and will be monitored for up to 10 years after treatment.
For the ALCHEMIST-Immunotherapy trials, patients will be randomly assigned to
receive nivolumab or just observation for up to 1 year.
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FOCUS4
FOCUS4 is a phase 2-3 randomized trial that uses the umbrella design to
evaluate different new therapies for patients with varying subtypes of advanced col-
orectal (bowel) cancer [183, 184]. The sub-types include mutations in the BRAF gene
(FOCUS4-A trial), in the PIK3CA gene (FOCUS4-B trial), in the KRAS or NRAS
gene (FOCUS4-C trial), no mutation in the above genes or all wild type (FOCUS4-D
trial) and unclassified biomarker results (FOCUS4-N trial). The primary outcome
measure is progression-free survival and overall survival as the secondary outcome
measure. multiarm multistage (MAMS) trial design methodology
Patients first will be followed after 16 weeks of standard first-line chemother-
apy. Once completed the chemo, if the tumor has not progressed, patients will be
screened for the sub-types. Within each sub-type trial, patients will be randomly
allocated to receive either a new treatment or a placebo or active monitoring.
FOCUS4-D patients will receive either AZD8931 or active monitoring. FOCUS4-
N patients will receive either capecitabine or active monitoring. Multiple interim
analyses are planned for early termination.
Between July 7, 2014, and March 7, 2016, the FOCUS4-D trial randomly
assigned 16 patients to receive AZD8931 and 16 patients to placebo. At first in-
terim analysis (March 2016), the independent data monitoring committee (IDMC)
recommended early termination due to lack of activity. At final analysis (August
2016), 15 with AZD8931 and 16 with place reached the primary endpoint. Median
progression-free survival was 2.96 months in the AZD8931 group and 3.48 groups in
the placebo group. No significant benefit of AZD8931 has shown over the placebo.
A new treatment replaces the current one for the FOCUS4-D trial.
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5.3 Signature Enrichment Design with Bayesian Adaptive Randomiza-
tion for Umbrella Trials
We extend the proposed cross-validated signature enrichment design with
Bayesian adaptive randomization to allow multiple experimental treatment arms
and add an early stopping rule that is suitable for umbrella trials (SEDAR-U). Sim-
ilar to SEDAR, we assume patient responses can be observed shortly after receiving
treatment. For the initial burn-in period, identical to SEDAR, we use equal random-
ization. The diagram for SEDAR-U is presented in Figure 5.2.
After the initial block, we enter an interim analysis to check the futility of
each experimental arm. If all arms fail, we terminate the study. If at least one
experimental arm passes, the trial continues. The first step is to derive a sensitive
patient classifier function (CF) to classify incoming patients into one of the two
categorize: sensitive and non-sensitive. Next, an enrollment function (EF) will be
applied to determine the probability of enrolling for each patient. Once the block
size of adaptive randomization is reached, patients are allocated among treatment
arms using Bayesian adaptive randomization. At the final analysis, we check the
efficacy of each experimental arm.
5.3.1 Sensitive-patient classifier function (CF)
Let r̂i,x,E and r̂i,x,C denote the estimated response rates for potential patient
i with signatures x if receiving treatment E or C, respectively. δ is the minimal
clinical meaningful difference for determining patient sensitive status. Then the
sensitive patient status is determined as follows:
• If r̂{i,x,E} − r̂{i,x,C} > δ, then patient i is sensitive;




























Figure 5.2: Diagram for Signature Enrichment Design with Bayesian Adaptive Randomization for
Umbrella Trials (SEDAR-U). CF is the classifier for determining patient sensitive status; EF is the
enrollment function; Pi is the probability of enrolling the i
th patient.
5.3.2 Enrollment function (EF)
Once a new patient’s sensitive status has been determined, the next step is
to calculate the enrollment probability. We use the following function for patient i
with signatures x:
Pi =
max(r̂{i,x,E} − r̂{i,x,C}, δ/10)
δ
.
According to this function, the probability for sensitive patients is 1 and that for
non-sensitive patients is between 0.1 and 1.
5.3.3 Bayesian adaptive randomization for multi-arms
Let k denote the treatment arm index, k = 1, ..., K; E for experimental arms
or C for control arm; n for the intermediate sample size, n = 1, ..., N ; and πk for
the response probability for arm k. Bayesian adaptive randomization assumes the
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randomization probability rk,n is proportional to the posterior probability [155]:
Pr(πk = max{π1, ..., πk}| datan), k = 1, ..., K,
When n is small, the posterior probabilities can be highly variable. To stabilize the
randomization probability, we add a tuning parameter w such that
rwk,n =
(Pr(πk = max{π1, ..., πk}| datan))w∑K
j=1(Pr(πj = max{π1, ..., πk}| datan))w
.
The value of w should be between 0 and 1. When w is equal to 0, it gives equal
randomization. When w is equal to 1, the rwk,n is the same as r̂k,n = P̂ r(πk =
max{π1, ..., πk}| datan). In practice, w is usually set at 1/2.
Another method to control the randomization magnitude is to let the posterior
probability be the randomization probability rk,n, and restrict it between [σ, 1 − σ]
where σ is a pre-specified value between 0 and 0.5.
5.3.4 Final sensitive subset
Similar to the cross-validated adaptive signature design, we use K-fold cross-
validation to obtain a final sensitive subset from the entire trial patients. First, the
entire trial population is randomly partitioned into M nonoverlapping equal-sized
subpopulations; Then, one of the M folds is used as the validation cohort and the
rest M − 1 folds are treated as the development cohort. Then for each fold, we
develop a sensitive patient subset Sm (m = 1, ...,M). Then the total number of the
sensitive patient subset from the entire trial patients is S =
⋃K
m=1 Sm.
5.3.5 Early futility stopping rule and final selection rule
For each πk, k = 1, ..., E, we use a non-informative prior Beta(1, 1).
We apply an early stopping rule for experimental arms at interim analysis
(after the initial block of patients):
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Experimental arm k is terminated due to futility if:
P̂ r(πk > πc + δ | dataINT ) < 0.01, k = 1, ..., K.
At final analysis, arm k is claim efficacious/selected if
P̂ r(πk > πc + δ | dataFNL) > aU , k = 1, ..., K,
where aU is a cut-off parameter whose value is determined/tuned to control the type
I error rate under the null scenario.
5.4 Trial Performance Evaluation Criteria
Similar to SEDAR, in addition to the most commonly used response rates and
power, we propose the following four criteria to further evaluate the trial performance
for precision medicine settings:
• Current individual loss (CIL)
• Future individual loss (FIL)
• Probability of a current individual in the trial receiving personalized optimal
treatment (PCO)
• Probability of a future individual receiving personalized optimal treatment (PFO)
The details can be found in chapter 4 section 4.4. To summarize, the penalties
for non-matches depend on the individual loss for CIL and FIL. While for PCO and
PFO, all non-matches receive the same penalty. Good clinical trial designs should
result in small values for CIL and FIL and large values for PCO and PFO.
5.5 Required Design Parameters
The required design parameters for SEDAR-U is listed in Table 5.1. We re-
quire the sample size for the initial equal randomization block (N0) for the adaptive
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randomization blocks (Nbar); tuning parameter w for allocation probabilities; mini-
mal clinical difference for sensitive status classification δ; minimal clinical difference
for early stopping rule and final selection rule γ; the type I error rate for testing
the overall treatment effect (α1) and that for testing treatment effect in the sensitive
subset (α2), and the prior for final decision rule and for BAR procedure.
Table 5.1: Design parameters required for SEDAR-U.
N0 Sample size for the initial equal randomization block
Nbar Sample size for adaptive randomization blocks
N Total sample size
w Tuning parameter for allocation probabilities
δ Minimal clinical difference for sensitive status classification
γ Minimal clinical difference for early stopping rule and final selection rule
α1 Type I error rate for testing treatment effect in overall patient group
α2 Type I error rate for testing treatment effect in sensitive subset
α Type I error rate for testing treatment effect in either overall patient group
or sensitive subset
Prior for BAR procedure and for rk
5.6 Simulation Studies for Multiple Treatment Arms with Control
We performed a series of simulation studies to explore the performance of our
proposed design that are suitable for umbrella trials. Similar to the previously signa-
ture Enrichment Design with Bayesian Adaptive Randomization for two treatments,
we compare our proposed design with the cross-validated adaptive signature design
and the adaptive enrichment design. For the adaptive enrichment design. At the
end of the trial, for all the designs, we use cross validation to seek sensitive patient
subset utilizing all the patient data. We are also vary the number of biomarkers
to study its effect on the trial performances. Here we investigate three simulation
categories: 1) with one control arm and ten biomarkers; 2) with one control arm and
two biomarkers; 3) without control arm and two biomarkers. For all scearios, we
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consider three treatments. The bivariate treatment indicators are
(5.1) (T1i, T2i) =

(1, 0) if patient i receives A
(0, 1) if patient i receives B
(0, 0) if patient i receives C (control)
We consider a three-arm clinical trial designed to compare two experimen-
tal treatments (A, B) with a control treatment (C ). We generate the ith patient’s
response from the following logistic regression model with ten biomarkers:
logit(ri) = β0 + β1T1i + β2T2i + η1T1iX1i + η2T2iX1i, i = 1, · · · , N.
where Xki is the k
th biomarker/signature for patient i. Each biomarker Xki is as-
sumed to follow a multivariate normal distribution (0.5,Σ) with correlation coeffi-
cient ρ. The prior for each regression coeficient is β0, β1, β2, η1, η2 ∼ Normal(0, 0.01),
where 0.01 refers to the precision.
Simulation setting
The total sample size N is set at 300; the size of each adaptive randomization
block Nbar is set at 50. We choose the size N0 of the initial block, for which equal
randomization is used, to be N0 = 150. Hence, we have a total of 4 blocks of sizes
150, 50, 50, and 50. The tuning parameter for Bayesian adaptive randomization
w is set at 0.5; the minimal clinical difference for sensitive status classification is
0.15, and for early stopping rule and final selection rule is 0; the type I error rate
α1 for testing overall treatment effect is controlled at 0.03; the type I error rate α2
for testing treatment effect in each sensitive subset is controlled at 0.01. Thus, the
total type I error rate for testing treatment effect in either overall patient group or
sensitive subset α is controlled at 0.05. The prior distribution of the response rate
for each treatment, rk, is assumed to be non-informative with Beta(1, 1).
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Similar to the simulation scenarios in chapter 4, we consider three biomarker
distributions. For each type, we include two scenarios and a null scenario to compare
the performance of SEDAR with ASD and AED (Table 5.2). The biomarker or
biomarker-treatment interaction effects not presented in the table are assumed to be
zero.
For the first category, we assume all biomarkers are independently distributed
following a normal distribution with mean 0.5 and variance 1.0. For the second cat-
egory, we assume the first five biomarkers have a multivariate normal distribution
X ∼ NVM(0.5,Σ) with the covariance matrix, which has 1 for the variance and
0.25 for ρ. The other five variables are still independently distributed with a normal
distribution with mean 0.5 and variance 1.0. For the third category, we assume the
first five biomarkers have a multivariate normal distribution with mean 0.5 and co-
variance matrix with ρ = 0.25, and the remaining five biomarkers have a multivariate
normal distribution with mean 0.5 and covariance matrix with ρ = 0.75.
All the categories and scenarios are listed in Table 5.2. The null scenarios for
each category numbers 1, 4, and 7, respectively. For scenarios 2, 5 or 8, we consider
the main treatment effect only for T1 and the corresponding treatment interaction
between T1 and X1, T2 and X1 will affect the patient response with different scales.
For scenarios 3, 6 or 9, we assume both the main treatment effect of T1 and T2,
and each of their biomarker-treatment interactions with X1 will affect the patient
response with different scales. For each scenario, we generated 2,000 simulations.
Simulation results
We compare the results obtained using our proposed design with those ob-
tained using ASD and AED. The results for the estimated power are presented in
Table 5.3. The type I error rates for the treatment effect in the overall patient group
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Table 5.2: Simulation scenarios - SEDAR-U.
β0 β1 β2 η1 η2
x1 to x10 with ρ = 0.00 Scenario 1 -0.8 0.0 0.0 0.0 0.0
Scenario 2 -0.8 0.2 0.0 1.6 1.2
Scenario 3 -0.8 0.5 0.3 0.8 0.2
x1 to x5 with ρ = 0.25 Scenario 4 -0.8 0.0 0.0 0.0 0.0
x6 to x10 with ρ = 0.00 Scenario 5 -0.8 0.2 0.0 1.6 1.2
Scenario 6 -0.8 0.5 0.3 0.8 0.2
x1 to x5 with ρ = 0.25 Scenario 7 -0.8 0.0 0.0 0.0 0.0
x6 to x10 with ρ = 0.75 Scenario 8 -0.8 0.2 0.0 1.6 1.2
Scenario 9 -0.8 0.5 0.3 0.8 0.2
and each sensitive subgroup are controlled at 0.03 and 0.01, respectively. The com-
posite type I error rate, which measures the probability of claiming that there is a
significant treatment effect found in either overall group or at least one of the sensi-
tive subsets when there is indeed no difference, is controlled at 0.05. The control of
the type I error rates are shown under the null scenarios in Table 5.3.
For the alternative scenarios, where there is indeed some treatment effect,
ASD has the highest overall power, following by AED and SEDAR. Though for
the composite power, the differences among all three designs become minimal. For
example, in scenario 6, the composite power for ASD, AED and SEDAR are 0.944,
0.940 and 0.937, respectively. In the sensitive subgroup, the relative performance
would depend on the underlying true treatment effects in the setting. When the
effect of treatment A is substantial and much larger than that of treatment B, the
power in sensitive patient subset to treatment A is similar among all designs. Also
note that the power of the treatment effect among patients who are sensitive to
treatment A is higher than that among the overall patient group. This reflects
the scenarios of precision medicine. When the effect of treatment A is moderate,
its power in the sensitive subset of ASD and SEDAR may be higher than AED.
For example, in scenario 9, the power of treatment effect among patients who are
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sensitive to treatment A is 0.752 for ASD, 0.744 for AED and 0.762 for SEDAR.
Table 5.3: Simulation results: Type I error rate/Power - SEDAR-U.
SCEN Parameters Design Overall Sensitive (A) Sensitive (B) Composite
1 NULL ASD 0.031 0.011 0.010 0.052
(Type I error rate) AED 0.027 0.009 0.009 0.045
SEDAR 0.028 0.011 0.009 0.048
2 β1 = 0.2, β2 = 0.0 ASD 0.939 0.972 0.600 0.988
γ1 = 1.6, γ2 = 1.2 AED 0.939 0.971 0.610 0.983
SEDAR 0.920 0.950 0.600 0.974
3 β1 = 0.5, β2 = 0.3 ASD 0.932 0.760 0.269 0.948
γ1 = 0.8, γ2 = 0.2 AED 0.926 0.742 0.263 0.942
SEDAR 0.916 0.764 0.279 0.931
4 NULL ASD 0.028 0.010 0.012 0.049
(Type I error rate) AED 0.027 0.010 0.012 0.048
SEDAR 0.029 0.010 0.009 0.048
5 β1 = 0.2, β2 = 0.0 ASD 0.950 0.978 0.636 0.989
γ1 = 1.6, γ2 = 1.2 AED 0.933 0.967 0.601 0.986
SEDAR 0.924 0.958 0.608 0.977
6 β1 = 0.5, β2 = 0.3 ASD 0.933 0.765 0.293 0.944
γ1 = 0.8, γ2 = 0.2 AED 0.929 0.735 0.267 0.940
SEDAR 0.921 0.762 0.282 0.937
7 NULL ASD 0.027 0.009 0.010 0.046
(Type I error rate) AED 0.030 0.008 0.011 0.049
SEDAR 0.031 0.012 0.011 0.053
8 β1 = 0.2, β2 = 0.0 ASD 0.951 0.970 0.636 0.989
γ1 = 1.6, γ2 = 1.2 AED 0.944 0.960 0.601 0.986
SEDAR 0.925 0.956 0.608 0.977
9 β1 = 0.5, β2 = 0.3 ASD 0.942 0.752 0.267 0.955
γ1 = 0.8, γ2 = 0.2 AED 0.936 0.744 0.275 0.949
SEDAR 0.932 0.762 0.292 0.948
The results of the four trial performance evaluation criteria are presented in
Table 5.4. Since both ASD and AED adopt equal randomization, the number of
patients is similar in each treatment arm. Thus, the ORR is the same for ASD
and AED. However, SEDAR uses adaptive randomization to assign more patients
to the superior treatment as trial proceeds, unlike ASD or AED which uses equal
randomization, SEDAR always achieves a higher objective response rate (ORR) than
the others. For example, in scenario 6, 45.1% of patients respond to the assigned
treatment for SEDAR compared to 41.0% for ASD and 40.9% for AED.
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The CIL and FIL show the average values of the individual loss for trial par-
ticipants and for future patients, respectively. For CIL, SEDAR has the smallest
values following by ASD and then AED. Using scenario 3 as an example, the CIL
for SEDAR is 0.284 compared to 0.337 for ASD and 0.342 for AED. This difference
in CIL shows that SEDAR results in more trial participants receiving their opti-
mal personalized treatments. For FIL, the results are similar for all three designs.
Those results suggest that the situation is more complicated when there are multiple
treatments and early stopping rules involved.
For the PCO values, SEDAR demonstrates that it offers the highest proba-
bility for trial participants to receive their personalized optimal treatments. This is
achieved by assigning more patients to superior treatment instead of using a fixed
ratio assignment method. The SEDAR also shows promising results for PFO, which
refers to the probability for a future patient to receive their personalized optimal
treatment if following the treatment recommendation from the trial.
To further investigate the patient allocation from applying Bayesian adap-
tive randomization, we take a look at the number of patients by treatment arm
(Table 5.5). Since there is virtually no treatment effect under the null scenarios,
Bayesian adaptive randomization acts the same as equal randomization by assign-
ing the same number of patients to each treatment arm. For alternative scenarios,
Bayesian adaptive randomization manages to assign many more patients to the truly
superior treatment and much fewer patients to the control treatment compared to
equal randomization. For example, in scenario 6, the number of patients assigns to
treatment A is 143 for SEDAR and 100 for ASD and AED. This clearly demon-
strates the advantages of Bayesian adaptive randomization, especially when the new
treatment could bring substantial benefits to patients.
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Table 5.4: Simulation results: Trial performance evaluation criteria - SEDAR-U.
SCEN Design ORR CIL FIL PCO PFO
1 NULL ASD 0.310 0.000 0.000 1.000 1.000
AED 0.310 0.000 0.000 1.000 1.000
SEDAR 0.310 0.000 0.000 1.000 1.000
2 β1 = 0.2, β2 = 0.0 ASD 0.420 0.314 0.057 0.333 0.703
γ1 = 1.6, γ2 = 1.2 AED 0.420 0.329 0.053 0.333 0.788
SEDAR 0.455 0.274 0.060 0.437 0.764
3 β1 = 0.5, β2 = 0.3 ASD 0.410 0.337 0.037 0.333 0.710
γ1 = 0.8, γ2 = 0.2 AED 0.410 0.342 0.042 0.333 0.774
SEDAR 0.451 0.284 0.044 0.445 0.764
4 NULL ASD 0.310 0.000 0.000 1.000 1.000
AED 0.310 0.000 0.000 1.000 1.000
SEDAR 0.310 0.000 0.000 1.000 1.000
5 β1 = 0.2, β2 = 0.0 ASD 0.420 0.314 0.057 0.333 0.701
γ1 = 1.6, γ2 = 1.2 AED 0.420 0.329 0.052 0.333 0.789
SEDAR 0.455 0.274 0.059 0.438 0.767
6 β1 = 0.5, β2 = 0.3 ASD 0.410 0.337 0.037 0.333 0.710
γ1 = 0.8, γ2 = 0.2 AED 0.409 0.342 0.040 0.333 0.778
SEDAR 0.451 0.284 0.043 0.445 0.769
7 NULL ASD 0.310 0.000 0.000 1.000 1.000
AED 0.310 0.000 0.000 1.000 1.000
SEDAR 0.310 0.000 0.000 1.000 1.000
8 β1 = 0.2, β2 = 0.0 ASD 0.420 0.314 0.059 0.333 0.696
γ1 = 1.6, γ2 = 1.2 AED 0.420 0.329 0.054 0.333 0.781
SEDAR 0.455 0.273 0.060 0.439 0.760
9 β1 = 0.5, β2 = 0.3 ASD 0.409 0.338 0.040 0.333 0.702
γ1 = 0.8, γ2 = 0.2 AED 0.409 0.343 0.043 0.333 0.769
SEDAR 0.450 0.285 0.046 0.444 0.757
5.7 Summary
In the modern era of cancer research, the evolution of clinical trial designs
calls for novel trial designs with improved efficiency and flexibility without under-
mining the validity and integrity. Among the newly proposed concepts, umbrella
trials target multiple genetic mutations with different treatments for a single cancer
type. Umbrella trials screen for patient molecular profiles and then assign treatments
accordingly. This procedure provides patients more trial options and allows a better
“fit” between the studies and patients.
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Table 5.5: Simulation results: Number of patients by treatment arm - SEDAR-U.
SCEN Parameters Design # in arm A # in arm B # in arm C
1 NULL ASD 100.0 100.0 100.0
AED 100.0 100.0 100.0
SEDAR 100.0 99.0 101.0
2 β1 = 0.2, β2 = 0.0 ASD 100.0 100.0 100.0
γ1 = 1.6, γ2 = 1.2 AED 100.0 99.9 100.2
SEDAR 135.7 94.3 69.9
3 β1 = 0.5, β2 = 0.3 ASD 100.0 100.0 100.0
γ1 = 0.8, γ2 = 0.2 AED 99.9 99.9 100.2
SEDAR 142.4 89.1 68.5
4 NULL ASD 100.0 100.0 100.0
AED 100.0 100.0 100.0
SEDAR 100.0 99.0 101.0
5 β1 = 0.2, β2 = 0.0 ASD 100.0 100.0 100.0
γ1 = 1.6, γ2 = 1.2 AED 100.1 100.1 100.0
SEDAR 135.8 94.4 69.8
6 β1 = 0.5, β2 = 0.3 ASD 100.0 100.0 100.0
γ1 = 0.8, γ2 = 0.2 AED 99.9 100.1 100.0
SEDAR 142.7 88.9 68.4
7 NULL ASD 100.0 100.0 100.0
AED 100.0 100.0 100.0
SEDAR 100.0 99.0 101.0
8 β1 = 0.2, β2 = 0.0 ASD 100.0 100.0 100.0
γ1 = 1.6, γ2 = 1.2 AED 100.1 100.0 99.9
SEDAR 136.1 94.0 70.0
9 β1 = 0.5, β2 = 0.3 ASD 100.0 100.0 100.0
γ1 = 0.8, γ2 = 0.2 AED 99.9 100.1 100.0
SEDAR 141.9 90.2 68.0
In this chapter, we have extended the cross-validated signature enrichment
design with Bayesian adaptive randomization to allow multiple treatment settings
with an early stopping rule which is suitable for umbrella trials. In addition to the
advantages of the cross-validated adaptive signature design and the adaptive enrich-
ment design, our design applies the Bayesian adaptive randomization method for
multi-arm and includes an early futility stopping rule. After the initial block of pa-
tients data became available, at the interim analysis, we apply an early stopping rule
which allows early termination of the study if all the experimental arms show futility.
If at least one experimental treatment passed the interim analysis, the proceeding
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steps are similar to the cross-validated signature enrichment design with Bayesian
adaptive randomization in chapter 4. That is, we enroll patients using an adaptive
enrichment approach by developing a sensitive patient classifier to oversample sensi-
tive patients and undersample non-sensitive patients. Once a patient enters the trial,
we use Bayesian response-adaptive randomization for multi-arms to adjust allocation
probabilities among the remaining arms. At the final analysis, we declare if each of
the remaining arms is efficacious based on a Bayesian decision rule.
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CHAPTER 6
Conclusion and Future Work
Clinical trial in the era of precision medicine promotes innovation in trial
design to answer more questions in less time. Adaptive clinical trials allow pre-
specified modifications on one or more trial components in the process so that more
enrolled patients could benefit from participating in the trial and result in expedited
drug development. After determining a safe and effective dose in phase I clinical
trial, phase II clinical trial assesses if the new treatment works that can then be
further evaluated in phase III clinical trial. In this dissertation, we mainly focus on
developing a novel design for phase II clinical trials.
In chapter 3, we compared different Bayesian response-adaptive randomiza-
tion methods and discussed their applications from both methodological and ethical
aspects. Bayesian response-adaptive randomization allocates more patients to the su-
perior treatment arms based on posterior probabilities, which is repetitively updated
based on accumulating trial data. Our simulation studies demonstrate that Bayesian
response-adaptive randomization results in more responders than ER, therefore dis-
play higher patient response rates.
In chapter 4, we proposed a signature enrichment design with Bayesian response-
adaptive randomization (SEDAR) focusing on cancer clinical trials. In addition to
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elements of ASD and AED, the proposed design uses an enrichment strategy to
enroll patients and applies Bayesian response-adaptive randomization for patient al-
location. As a result, SEDAR offers more advantages, in addition to the ones of ASD
and AED. Also, we proposed four trial evaluation criteria that can be used to better
evaluate the performance of trial design for precision medicine. Extensive simulation
studies show that SEDAR presents more favorable characteristics than the other two
designs. We also present an example based on the IPASS trial.
In chapter 5, we extended SEDAR to incorporate multiple treatments and
add an early stopping for futility. Those elements are suitable for umbrella trials.
Umbrella trial is a type of master protocols, which studies multiple treatments with
each in a biomarker enriched sub-study for one disease type under one overarching
protocol. Our simulation studies demonstrate that the proposed signature enrich-
ment design with Bayesian adaptive randomization for umbrella trials (SEDAR-U)
offers more benefits to the trial participants than the alternative designs.
In contrast to umbrella trials, basket trials evaluate the test treatment for
multiple disease types but with common molecular alteration(s). Basket trials often
require a fewer number of patients and result in a shorter duration than the tradi-
tional phase II trial. Also, the basket trial can be especially useful for rare molecular
aberrations as the data may be pooled across substudies for analysis. Many de-
signs for basket trials have been proposed that allow borrowing information across
cancer types to improve the statistical power while controlling the type I error rate
[185, 186, 187, 188, 189]. One future work could be to extend SEDAR for basket
trial.
In this dissertation, we focus on a single primary endpoint. Trial designs that
use more than one primary endpoint may offer a more comprehensive evaluation of
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the treatment effect than ones that are using the single endpoint. In 2017, the US
Food and Drug Administration (FDA) issued guidance regarding the use of multi-
ple endpoints in clinical trials [190]. When designing a trial that uses co-primary
endpoints to evaluate the joint effect of all the endpoints, the type II error needs to
be controlled as it inflates with an increasing number of endpoints [191, 192]. For
hypothesis testing, co-primary endpoints use the intersection-union principle [193].
The null hypothesis is rejected if and only if all hypotheses with each corresponding
to each endpoint are rejected. Many designs and analyses have been proposed for
co-primary endpoint trials [194, 195, 196, 197]. Extention of the SEDAR design to
allow co-primary endpoints still warrants future research works.
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